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ABSTRACT 
Growth charts are inevitable tools for following children in clinical practice and also when 
evaluating growth promoting therapy. Growth is a concern especially for families to children 
of extreme short stature such as in skeletal dysplasias but evaluations of growth pattern with 
changes in height position is complicated when height develops far below normal population 
range. Height gain from growth hormone therapy is variable for short stature conditions 
without aberrant growth hormone secretion such as in Turner syndrome. This makes it 
difficult to communicate realistic adult height estimates to concerned families. 
The first part of this PhD project used semi-longitudinal data from 4,375 measuring 
occasions to construct growth and body proportion references for achondroplasia and to 
describe these in relation to normal population references. Typical for achondroplasia, tempo 
in head size was increased attaining final size earlier than normal. Height was at the same 
time compromised with major loss in height position during the first years of life, due to 
limited growth capacity of the legs. At adult ages, leg length was half of that in normal 
population and arm span almost 35 percent lower than normal contributing to severely 
reduced area of personal access. Pronounced body disproportions distort the BMI-value in 
achondroplasia, which is why specific BMI charts were constructed. 
Clinical achondroplasia charts were developed to support surveillance of these children and, 
as short stature matrix, possibly also for other children with severe short stature for which 
syndrome-specific charts are missing. The usability of these achondroplasia charts were 
tested by illustrating growth pattern of selected skeletal dysplasias. 
Obtained achondroplasia references for height, sitting height, leg length and arm span might 
contribute to a better understanding of the effect of FGFR3 signalling on growth and will also 
be inevitable tools for evaluation of novel treatments. 
In the second part, variability in response to growth hormone therapy was studied by dividing 
a sample of 455 girls with Turner syndrome, reported in the Swedish National Register for 
growth hormone treatment of children and adolescents, into good and poor response based on 
the distribution of total height gain from treatment. As age at treatment initiation was 
distributed over almost entire growth period, the sample was further grouped into those with 
treatment start during normally prepubertal and pubertal ages. Differences of clinical 
relevance were higher mid-parental height, higher GH dose at 12 months of treatment and 
improved body proportions in the younger good response group; and younger age and shorter 
height position at treatment initiation and higher GH dose in the older good response group. 
These findings could possibly be influenced by subgroups identified in graphic presentations. 
Initial height gain from treatment did not necessarily translate into better total height gain 
neither in younger or older poor groups. In contrast to previous claims, early initiation of 
growth hormone treatment per se did often not result in better total height gain. 
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LIST OF ABBREVIATIONS 
AMDM AcroMesomelic Dysplasia type Marotaux, a severe short stature skeletal 
dysplasia caused by homozygous or compound heterozygous mutations 
in NPR2 gene, which encodes natriuretic peptide receptor B (NPR-B) 
APHV Age at Peak Height Velocity, period with maximum rate of growth 
during pubertal development 
Auxology Science of somatic growth and development 
Centile/Percentile A certain position in a growth chart expressed as percentage of the 
observations below this position; e.g. 3 percent of all observations can 
be found below the 3rd centile. 
COMP Cartilage Oligomeric Matrix Protein, an extracellular protein important 
for structural assembly of extracellular matrix 
CV Coefficient of variation, measure of dispersion or variability, equals to 
S-parameter in LMS method 
edf-values effective degrees of freedom values to specify the degree of smoothness 
of the LMS curves; e.g. a higher edf value will result in a less smooth 
curve 
FGFR3 Fibroblast Growth Factor Receptor 3, heterozygous activating mutations 
in the FGFR3 gene cause achondroplasia and hypochondroplasia 
GAMLSS Generalised Additive Models for Location, Scale and Shape are 
univariable distributional regression models where all parameters of an 
assumed distribution for the response can be modelled as additive 
functions of the explanatory variable 
GH Rx Growth Hormone treatment 
KIGS Pfizer International Growth Database, postmarketing register for growth 
hormone treatment 
LMS method Lambda-Median-Sigma method for constructing normalised growth 
reference by modelling Box-Cox power (L), median (M) and coefficient 
of variation (S) 
MPH Mid-Parental Height, average height of parents calculated by average of 
parents’ height SDS or parents height in cm with ±6.5 cm adjustment for 
sex of the child (i.e. +6.5 cm for boys and -6.5 cm for girls) 
ISS Idiopathic Short Stature, children with height below -2 SD without 
clinical features of a syndrome, endocrine or disorders or other 
noticeable cause for short stature  
NPR2 Natriuretic Peptide Receptor 2 gene, which encodes natriuretic peptide 
receptor B (NPR-B). Biallelic loss of NPR2 function results in AMDM 
PSACH PSeudoACHondroplasia, a short limb and short trunk skeletal dysplasia 
caused by heterozygous mutations in the gene encoding COMP 
SD Standard Deviation, measure of variance 
SD bandwidth the “size of SD” in data of non-normal distribution as distance between 
one SD line to the next SD line; e.g. the area between +1 and +2 SD 
SDS/ z-score Standard Deviation Score, a position in the growth chart, i.e. relative to a 
given reference, calculated as SDS = (Measurement-Mean)/SD at a 
given age for a variable that follows a normal distribution (e.g. height). 
In variables that contain skewness (e.g. weight), SDS can be calculated 
from LMS values as SDS = ((Measurement/M)L-1)/LS 
SILL SubIschial Leg Length, measured as difference between height and 
sitting height 
SITAR SuperImposition by Translation And Rotation, a shape invariant model 
that adjusts individual height curves for their size, tempo and velocity 
and results in a mean curve and a value of these three parameters 
SH/H Sitting Height/ Height ratio; i.e. relative sitting height, as measure of 
body proportion 
SLC26A2 SoLute Carrier 26A2 a gene coding for a sulphate transporter important 
for production of proteoglycans 
SHOX Short Stature HomeoboX gene, heterozygous defects in SHOX or 
deletion of its downstream regulatory domain result in Leri-Weill 
dyschondrosteosis, a skeletal dysplasia with mild phenotype, and 
homozygous defects of SHOX cause the more severe Langer mesomelic 
dysplasia 
TS Turner syndrome, chromosomal condition with one missing or 
structurally altered X chromosome in females 
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1 INTRODUCTION 
The wide variation of short stature conditions ranging from mild to severe phenotypes teach 
us how many factors are involved in normal growth and what role single genes can have. 
Severe short stature, especially of familial trait, often has a monogenic background but in the 
normal population, only a small variation in height may be explained by the hundreds of 
genes so far found to be associated with height.1 Genome-wide association studies from 
hundreds of thousands of individuals identified 780 variants together explaining 27 percent of 
variation in adult height.2 Of special interest is that somatotropic axis, i.e. various 
components of GH, IGF-I, insulin, signalling has no particular role in this assembly. 
However, population studies in Peru found a special variant of fibrillin 1 (FBN1) that may 
contribute to a short height in Peruvians, about 2.2 cm deduction in those with one copy and 4 
cm in those with 2 copies3. Pathogenic variants in FBN1 may, on the other hand, result in 
extreme tall stature, Marfan syndrome, or extreme short stature, acromicric dysplasia. 
1.1 GROWTH IN HEIGHT AND BODY PROPORTIONS 
In addition to height also development of body segments, such as sitting height and leg 
length, is of interest when analysing growth regulation. Trends in height in a population over 
time, i.e. secular trends, are partly dependent on leg growth,4,5 which generally is considered 
to be sensitive to environmental conditions.4 Sitting height, as proxy for growth of the spine, 
is furthermore stimulated by pubertal sex hormones. Trunk and legs develop therefore at 
different tempi, as can be evaluated as percentage of final size and as yearly increments in 
Figure 1. It is clear that the majority of growth in legs occurs postnatally and predominately 
during prepubertal ages. Legs stop growing more abruptly while the pubertal spurt in sitting 
height, being more intensive, fades away slowly.6 
Body proportion, such as sitting height as percentage of height (“relative sitting height”), 
therefore changes with age. Sitting height/ height ratio decreases fast, from 68 percent at one 
year to 51 percent in male and 53 percent in female adults.7 Body disproportions are, 
however, also a typical feature of skeletal dysplasias and can therefore teach us what 
mechanisms might be involved in the regulation of leg versus spine growth. 
It is worthwhile noting that head circumference, as proxy for brain size,8,9 follows a distinct 
growth pattern. Most of the final size is attained already by birth and head circumference 
grows rapidly approaching adult size during the first three years of life. 
Children from diverse ethnic and genetic backgrounds grow generally similar up to five years 
of age,10,11 suggesting that differences in height are established first from childhood ages. 
Genetic differences can also be found in body proportions; longer legs are more common in 
black Americans despite lower sitting and standing height than in white Americans.12 
Differences in growth might, however, not necessarily be limited to genetic differences, as 
studies on Maya children have shown. Those living in Guatemala were on average 11 cm 
shorter and 12 kg lighter than their relatives growing up in the USA.13 
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Figure 1 Development of height, head circumference, sitting height and leg length based on references from 4th Dutch 
nation-wide survey7,14: (a-b) as percentage of final size and (c-d) as yearly increments, i.e. differences between mean 
values of full chronologic ages. Note that birth values for height and head circumference represent values at 2 weeks 
of age. 
Individuals may vary in height or size but also in the speed for reaching final size; i.e. in 
tempo of growth.15 Differences in tempo might increase with age becoming more apparent 
during adolescent ages when the growth curve slope is steeper.15 Figure 2 illustrates height 
and height velocity between early, average and late maturational tempo. It is worthwhile 
mentioning that tempo is not associated to differences in final height. There is no or little 
evidence that timing of pubertal spurt or of attaining final height is related to final height15. 
Tempo in growth is primarily inherited,15 which can be demonstrated using age at menarche 
as proxy for developmental age and tempo. Timing of menarche is strongly influenced by 
genetic factors16 and mother-daughter and sister-sister correlations are close to 0.5.17 
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Figure 2 Height (cm) and height velocity (cm/year) development in an example of early, average and late maturational 
tempo. Illustration adapted from Hauspie and Roelants.15 
1.2 TARGET HEIGHT AND PREDICTORS OF ADULT HEIGHT 
Parental height can be used as a proxy of inherited growth size and tempo and gives an 
indication for a child’s adult height, or its target. Target height can be calculated as average or 
mid-parental height (MPH) with ±6.5 cm adjustment for sex of the child (i.e. +6.5 cm for 
boys/ -6.5 cm for girls) or as average of both parents height expressed in standard deviation 
score (SDS). Using SDS scale might be more robust.18 Taking into account a predicted 
confidence interval of 95% would result in a target height range ±10 cm for boys and ±9 cm 
for girls.19 Note that MPH might also have to be adjusted for assortative mating and the 
correlation between parental height,19 while others found no such effect.20 
The child’s current height position is another important predictor of its adult height; alone or 
in combination with MPH.19,21 The correlation coefficient is only 0.3 at birth but increases to 
above 0.7 at two years of age.22 Similar observations from the First Zürich Longitudinal 
Growth Study23 are summarized in Figure 3. Note that there is a dip during pubertal ages 
coinciding with age at peak height velocity.23 Relating bone age, as a measure of maturity, to 
adult height is, before pubertal ages, less informative than chronologic age.21,23 
The prepubertal height position can therefore give an indication of expected adult height. For 
girls with Turner syndrome, for which pubertal growth most often is compromised by ovarian 
failure, adult height is often estimated by projection of height position on syndrome-specific 
growth chart irrespective of age for this prediction.24 Alternative methods are based on the 
relationship between current height and adult height in historical, untreated (with growth 
hormone) cohorts of girls with TS24,25 or various indexes or methods including bone age.24 
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Figure 3 Child-adult height correlations based on individual data from the First Zürich Longitudinal Growth Study:  
(a) for chronological age and (b) comparing chronological age (CA) and bone age (BA) in boys (blue) and girls (red). 
Illustration adapted from Molinari et al.23 
1.3 GROWTH CHARTS 
A growth reference is a summary of the statistical distribution of an anthropometric measure 
and is for clinical purposes generally presented as a growth chart.8 As such, growth curves are 
essential tools for clinical practice and their layout should therefore facilitate usability for 
following an individual. Growth references are also used for screening of short stature 
conditions26 or disease27 or to follow growth in a population for instance for evaluating 
secular trends in height28,29 or in overweight and obesity.30–32 
1.3.1 Longitudinal versus cross-sectional references 
Growth references are useful for comparing differences among populations. Conclusions 
should, however, be drawn with caution since studies usually are based on different 
methodologies and vary in terms of focus group (e.g. dedicated social group, regional focus), 
exclusion criteria (e.g. breast-feeding, parental origin), prospective/ retrospective design, 
sample size and other factors. 
Most growth references today are based on cross-sectional surveys with each child 
contributing one measurement. This setup requires a representative sample across all ages and 
a higher sample size to capture growth in periods of increased velocity changes.33 Resulting 
references give, however, only a static picture of the variation.15 Variation in tempo and 
pubertal growth can only be obtained from longitudinal studies, 8,15,34,35 but these are time 
consuming and sensitive to drop-outs. A mix of both, i.e. semi-longitudinal, is therefore 
sometimes used, for instance in the WHO reference where growth during infancy is based on 
longitudinal cohorts36 and growth from school ages on historic health surveys.37 
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Figure 4 Mean ±2 SD in British height references34,35, conditional (longitudinal, dashed) and unconditional for tempo 
(cross-sectional, line): height slopes appear steeper and curve range narrower if adjusted for different tempi. 
The most important difference between longitudinal and cross-sectional references is their 
appearance during pubertal ages. The curves appear steeper with less variability if based on 
longitudinal data (Figure 4) since individual data series can be centered around average age at 
peak height velocity (APHV) hereby adjusting for differences in tempo. “Chronological age 
is thus replaced with age corrected for tempo.”15 References from cross-sectional surveys, on 
the other hand, are based on a mix of early, average and late maturing children,15 as seen in 
Figure 5, where variations in tempo and pubertal growth spurt are smoothed out.15,34,35 Tanner 
et al. referred to this phenomenon as “phase difference effect” and distinguished between 
growth standards “unconditional for tempo” and “tempo-conditioned”.34 
 
Figure 5 Differences in individual and mean height velocity during pubertal ages: (a) mean height based on cross-
sectional data and (b) mean height after centering individual data series around average age at peak height velocity. 
Illustration are adapted from Tanner et al.35 
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1.3.2 Measuring the child 
Accurate measurements require standardized measuring techniques and calibrated 
instruments. The child per se is often the main source of error since the result depends on 
how “elastic” the child is, which is influenced by his/her mood. Skeletal dysplasia specific 
handicap might also hamper the measurements. Cooperation with the child is therefore of 
central importance to obtain reproducible results. Additionally, time of the day for the 
measurement can play a role, especially for height and sitting height, because of the tendency 
to shrink during the course of the day due to compression of vertebral discs. 
Length of the supine body is generally measured up to two years of age and height of 
standing position thereafter, both following the protocol of Hall et al.38 In skeletal dysplasia it 
is not unusual to measure height in supine position even after two years of age since some 
conditions confer muscular hypotonia, ligamentous laxity and/or immature motor 
development or other difficulties to stand due to severity of disease. Length and height 
measurements might further be influenced by deformities such as thoraco-lumbar kyphosis, 
flexion contractures, bowed tibias, genu varum, marked lordosis or scoliosis. 
1.3.3 Growth curve modelling 
Modelling the height curve is more complex than might be imagined. This includes 
modelling of individual data series but also modelling of a group of individual data series 
(longitudinal data) or data points (cross-sectional data). Growth is limited by an individual’s 
potential and growth tempo determines the shape of his/her curve that may, however, be 
followed at two separate time points.39 Statistical analysis is further complicated by an 
individual’s measurements being related.39 
Simple modelling forms such as polynomials can result in a poor fit at both ends of the age 
range if the age range is wide.8 This can be avoided by fractional polynomials, which are 
based on an equation with selected age powers instead of successive integer age powers. 
Fractional polynomials are, however, ineffective when modelling events such as pubertal 
spurt or BMI infancy peak. As an alternative, parametric models for height are available for 
certain growth periods, such as Jenss-Bayley (four parameters) for infancy-childhood and 
Preece-Baines I (five parameters) for puberty/ adolescence, or for the whole growth process 
from birth to adult height, such as BTT (Bock-duToit-Thissen, 8 parameters), Shohoji-Sasaki/ 
Count-Gompertz (6 parameters), JPA-2 (Jolicoeur-Pontier-Abidi, 8 parameters)40 or ICP 
(Infancy-Child-Puberty, 9 parameters)6. These growth models might, however, not 
necessarily be good in catching unusual growth patterns6 nor be suitable for describing how 
variability changes with age.8 
Other popular methods are based on spline and kernel smoothing. These techniques use local 
moving averages based on weighting functions and bandwidth,8 that guide the smoothness of 
the curve that is otherwise estimated only from the primary data.39 Such a nonparametric 
approach is more sensitive to biologic variation in the data. Individual velocity curves can be 
estimated and analysed irrespective of how other series in the sample develop.6 Common 
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features are then combined in a model or shape function.6 The SITAR-model 
(SuperImposition by Translation And Rotation), for instance, estimates a fitted curve from 
individual curves that are matched by differences in size, tempo and velocity.41 More 
specifically, individual curves are shifted up/down (adjustment for size), left-right 
(adjustment for tempo) with the age scale being shrunk or stretched (adjusted for velocity).41 
The three parameters – size, tempo and velocity – can then be estimated, which may be 
powerful for comparing groups; e.g. in oxandrolone versus placebo treatment in girls with 
Turner syndrome.42 
Some growth references are constructed from the distribution of empirical data, which can, 
however, be biased in small samples and can also result in (extreme) centiles that touch or 
cross each other at extreme levels.8,33 Alternative approaches approximate the distribution of 
the data assuming that it follows a certain distribution. “Centiles are estimated by fitting the 
data to the (assumed) distribution, transforming to the normal scale to estimate the centiles, 
and then back-transforming to the original scale (of the measurement).”33 A normal 
distribution with two parameters (mean and SD) is suitable when variability is low, i.e. 
coefficient of variation is less than 5 percent,8 and is generally used for modelling height or 
head circumference for age. Centiles for weight and BMI are, however, better estimated by 
three-parameter distribution models, i.e. including Box-Cox power as an extra parameter for 
skewness.33 For review, see Borghi et al. 36 that summarizes 30 methods for constructing 
growth curves based on a comprehensive review of Wright and Royston, 1997. An innovative 
and resource saving method is to construct “synthetic” growth charts.43,44 Its latest version 
estimates most common factors or characteristics of a growth reference based on principle 
component analysis (PCA) of almost 200 growth studies.44 The first five components 
describe 98.7/ 98.4 percent of the male/ female variation in height, which thus can be used to 
construct synthetic curves for a selected population from a small sample.44 
 
Figure 6 L, M and S curve for BMI for age and sex in the WHO reference37,45 
Most growth references are today based on the LMS method, which summarises the 
distribution by three parameters: the Box-Cox power (L), the median (M) and the coefficient 
of variation (S). In its first version, these three parameters are estimated for pre-defined age 
groups and are then smoothed across ages.46 The choice of age groups can, however, 
influence the estimated reference curves33 and the current version uses therefore age as a 
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continuous variable and natural cubic splines for smoothing each of the three parameters.47 In 
short, model fitting includes finding the “right” shape of the LMS curves (Figure 6), which 
can be controlled by smoothers in form of effective degrees of freedom (edf) where choosing 
higher edf values gives a curve closer to the empirical data and lower edf values smoother 
curves. Some subjectivity remains therefore in the choice of smoothing parameter.33 
To apply this method, the LMSChartmaker Pro program can be used, which was for instance 
done for construction of references for normal population in Argentina48 or for skinfold 
thickness in normal German children.49 The LMS method is also implemented in Rigby & 
Stasinopoulos framework on generalised additive model for location, scale and shape 
(GAMLSS)50,51 and its R package GAMLSS. Here, models can also be compared based on 
model criteria, such as several forms of generalised Akaike Information Criterion (AIC). The 
model with the lowest model criterion value represents best fit.52 In other words, the goal is to 
find the edf value that minimises the model criterion. Model validation is performed based on 
the distribution of the residuals, either against fitted values or x-variable, or by normal QQ-
plots.52,53 This might sound straight-forward, yet it should be noted that curve fitting remains 
a subjective exercise or “black art”,47 since there is always a trade-off between empirical fit 
and smooth appearance.47,54 
1.3.4 Layout of growth charts 
Growth charts differ in terms of background populations but also to a great extent in their 
layouts; i.e. their format, scope/ spacing and general appearance. Some charts are presented in 
portrait, others in landscape format. Some focus on one variable per page while others 
combine several variables usually for age. In many countries traditional centile curves are 
used covering 5th to 95th or 3rd to 97th centile, while others use SD lines ±2, ±2.5 or ±3 SD. 
Note that both scales express the distribution of a given variable; a centile represents the 
percentage chance of lying below a given line while SD scale is centered on zero8. For 
variables that follow a normal distribution, -1, -2 and -3 SD correspond to respectively 15.9, 
2.3 and 0.14 centile. Both centile and SD scale can thus be used to express a position in the 
growth chart. 
Centiles might intuitively be easier to interpret since the position on the growth chart 
represents a rank between 0 and 100. Yet, centiles are not useful for following how a position 
changes with age53 nor for calculating descriptive statistics.33 This is because the same centile 
interval corresponds to different intervals of the measurement.33 A change of 10 centile points 
between the 60th and 50th centile, for instance, cannot be compared with a decrease between 
11th and 1st centile.53 Also substantial changes in height will result in very small centile 
changes at the extremes of a distribution.33 The z-score or SD score (SDS), on the other hand, 
is normalized and can therefore be compared across ages and sexes. These can be used 
beyond centile ranges53 and extreme height positions can thus be expressed in a “meaningful” 
way (Table 1). 
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Table 1 Centiles versus z-score/ SDS with examples of corresponding height position based on the WHO height 
reference37,45 
Centile z-score/ SDS Example 
50th ±0 normal average 
15.87 -1 “we are not so tall in our family” 
2.275 -2 delayed puberty 
0.135 -3 Turner and Down syndrome 
0.0032 -4 GH-deficiency 
0.00003002 -5 “must be a syndrome” 
0.0000002148 -6 achondroplasia 
0.0000000002746 -7 adult pseudoachondroplasia 
It is apparent that the linear development of height is limited to childhood ages. Capturing an 
entire growth period by linear axes gives equal spacing to the measure and thus neglects 
differences in growth velocity. In other words, the same focus on the age axis is given for 
growth during the first year of life as for the sixth year. Similarly, on the BMI axis the same 
focus is given for BMI between 29 and 30 kg/m2 as for between 15 and 16 kg/m2. From a 
biologic perspective this spacing might not always be reasonable. 
 
Figure 7 The Swedish growth chart for ages 0 to 24 months, 2 to 7 years and 5-18 years using extended (down to -5) 
SD lines here showing a clinical example of weight seemingly driving length during the first year of life in a girl. 
To minimise the problem of different growth velocities for age, many growth charts are 
available for separate age periods, allowing for less compression of the chart area. Following 
a child’s growth pattern over time might then be more difficult and require several charts. But 
height and weight charts are preferable combined on the same page since both measures 
should be evaluated in comparison to each other. Details on length/ height development is for 
instance of value in situations with extensive weight gain or loss. The Swedish growth chart, 
Figure 7, is therefore constructed on logarithmic scales to better capture height and weight 
development during the first years of life when growth velocity is highest.55 This approach 
increases sensitivity both in plotting and reading. 
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Another feature typical of the Swedish growth charts is prepubertal SD lines that are a 
projection of growth during childhood into pubertal ages. Similar lines are also constructed 
from a prepubertal cohort, up to 14 years in boys and 13 years in girls, in the latest Danish 
chart,56 thus representing growth of late maturers. 
1.4 WHEN GROWTH DEVELOPS OUTSIDE THE CURVE AREA 
While growth curves show an individual’s position within the population distribution per age, 
they may have limited accuracy for following a child’s growth pattern that develops outside 
the central distribution shown by the curve. For instance, Figure 8 depicts the height patterns 
of four boys with different skeletal dysplasias and extreme short stature. It is apparent that all 
of them grow far beyond the curve area, but a more precise evaluation is difficult. This 
hampers predicting a child’s growth pattern, monitoring whether additional medical 
conditions might be present and discussing height development over time with the families. 
Syndrome-specific growth charts are therefore essential. 
 
Figure 8 Individual height development in four boys with different skeletal dysplasias: achondroplasia (ACH in blue), 
acromesomelic dysplasia Maroteaux (AMDM in red), Kniest dysplasia (Kniest in green) and spondyloepiphyseal 
dysplasia congenita (SEDC in purple). Height position of all boys develops far beyond normal population range, here 
illustrated on ±3 SD WHO growth chart.37 
1.4.1 Skeletal dysplasias 
Skeletal dysplasia have historically been recognized and grouped based on radiologic 
evaluations.57 Clinical entities could therefore be distinguished based on typical features such 
as for instance short limbs-normal trunk (e.g. achondroplasia, dyschondrosteosis), short limbs 
and trunk (e.g. pseudoachondroplasia, diastrophic dysplasia, Kniest dysplasia), lethal forms 
of short-limbed dwarfism (e.g. thanatophoric dysplasia), increased limb length (e.g. Marfan 
syndrome) or decreased bone density (e.g. osteogenesis imperfecta).58 
Starting in the later 1990s, technological advances opened up for genetic explanations and 
confirmation.57 Skeletal dysplasias can therefore today also be grouped based on molecular 
defects such as for instance defects in extracellular matrix protein (e.g. collagen type I 
including osteogenesis imperfecta, collagen type II including Kniest dysplasia, cartilage 
ACH
SEDC
AMDM Kniest
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oligomeric protein (COMP) including pseudoachondroplasia), defects in metabolic processes 
including enzymes or transporters (e.g. solute carrier 26A2 (SLC26A2) affected in 
diastrophic dysplasia), defects in signalling pathways (e.g. fibroblast growth factor receptor 3 
(FGFR3) affected in achondroplasia and thanatophoric dysplasia, natriuretic peptide receptor 
B (NPR-B) affected in acromesomelic dysplasia type Maroteaux) or defects in nuclear 
protein or transcription factors (e.g. short stature homeobox gene (SHOX) affected in Léri-
Weill dyschondrosteosis).59 
The skeletal dysplasia family includes a wide range of genetically heterogeneous groups and 
entities that can be phenotypically overlapping. A straight-forward correlation between 
genotype and phenotype might be limited to certain clinical entities. On the other hand, a 
spectrum of mild-to-severe phenotype for similar genotype can be found in the FGFR3 
family (tall stature – hypochondroplasia – achondroplasia – thanatophoric dysplasia), in 
SHOX related dysplasias (tall stature – Léri-Weill dyschondrosteosis – Langer mesomelic 
dysplasia) as well as in NPR2 related dysplasias (tall stature – idiopathic short stature – 
acromesomelic dysplasia Maroteaux). 
The 9th and latest edition of skeletal dysplasia nosology from 2015 classifies 436 genetic 
disorders related to 364 genes into 42 groups.60 Some groups are based on affected genes 
covering various separate diagnoses, while other skeletal dysplasias are still grouped by 
radiographically or clinically similar entities. 
Achondroplasia is the most common and easily recognisable skeletal dysplasia with extreme, 
disproportionate short stature. The condition is caused by an almost uniform heterozygous 
mutation in FGFR361,62 that causes constitutionally increased activity of the receptor.63 
Endochondral growth is regulated by a balance between FGFR3 activity that restricts 
chondrocyte proliferation, hypertrophy as well as matrix production and growth promoting 
factors like C-type natriuretic peptide (CNP) and bone morphogenetic proteins (BMP’s) 
among others.63 In achondroplasia the negative FGFR3 influence overrides the growth 
promoting signalling mainly in the extremities, leaving the trunk (i.e. spine) to great extent 
unaffected.63 Typical clinical features besides extreme short stature and short, rhizomelic 
limbs are disproportional large head with frontal bossing, prominent buttocks, short fingers 
and limitation of elbow extension.64 
1.4.2 Skeletal dysplasia specific growth studies 
Specific growth references exist for more frequent growth disorders such as Turner 
syndrome65 and Down syndrome,66,67 but for many conditions knowledge of growth 
development is limited since the prevalence is very or extremely low making it unfeasible to 
construct growth and body proportion syndrome-specific references. In addition, many 
skeletal dysplasia conditions comprise quite heterogeneous diagnoses with considerable 
variability in phenotype both within and between families. Individuals with mild phenotypes, 
for instance in Léri-Weill dyschondrosteosis or hypochondroplasia, might then never be 
detected. Growth studies for these diagnoses are therefore not necessarily representative for 
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the genetic disorder if based on only the severe phenotype cases (and affected family 
members). In addition, mutation based references68 may comprise a wide range of clinical 
entities/ severity. 
There is remarkably little systematic information available on auxological variables in 
different skeletal dysplasias. Table 2 gives an overview of published growth references, 
growth studies and case reports including auxological data for selected skeletal dysplasias. 
Table 2 Summary of growth studies of skeletal dysplasias or case reports with anthropometric data 
Study 
Sample 
origin 
Variables 
collected 
Setting of data 
collection 
Sample size and 
data collection 
period 
Presentation of results Comment 
Achondroplasia, ACH 
Murdoch 
et al., 
197069 
USA Height Questionnaire, 
national and 
district meetings 
of the Little 
People of America 
(LPA) 
73 males/ 75 females 
majority born 1917-
1966 
Birth length, adult height, parental 
ages 
Individual data in appendices  
Diagnosis 
made by 
medical 
geneticists, 
many cases 
confirmed by 
radiology 
Nehme 
et al., 
197670 
USA Height  
Sitting height 
Leg length 
Sitting height/ 
Height (crown 
rump to crown 
heel ratio) 
Femur, tibia, 
fibula 
Hand, wrist 
Weight 
Foot length 
Clinical 
measurements at 
Children’s 
Hospital Medical 
Centre, Boston 
Massachusetts 
11 males/ 7 females  
aged 5 mo to 18 yrs 
70 examinations 
Average height and sitting height 
development, 1-18 yrs in boys and 
girls (charts only) 
Standard deviation of height, 
sitting height, ratio sitting height/ 
height, length tibia and femur, 1-
18 yrs (chart only) 
Relative height, sitting height, ratio 
sitting height/ height, length tibia 
and femur and weight per sex and 
age group 0-3 yrs, 4-10 yrs, 11-14 
yrs, 15-18 yrs (table) 
Diagnosis 
based on 
radiological 
features 
Horton  
et al., 
197871 
USA Height 
Height velocity 
Head 
circumference 
Upper/lower 
body segment 
Short stature 
clinics at medical 
institutions in 
Torrance, Seattle 
and Houston, 
1976 National 
LPA Convention 
189 males/ 214 
females 
longitudinal data: 
height 189/ 214 
height velocity 26/ 35  
upper/ lower 75/ 95 
head 114/ 145 
Sex-specific mean ±2 SD 
references for head 
circumference, height and height 
velocity, 0-18 yrs and for upper 
and lower segment, 2-18 yrs 
(charts only) 
 
Wynne-
Davies  
et al., 
198172 
UK Height 
Arm span 
Visits traced from 
records of 8 
hospitals 
48 individuals 
 
Height scatter plot, 0-35+ yrs, 
sexes combined (chart only) 
Span scatter plot, 0-35+ yrs, 
sexes combined (chart only) 
Diagnosis 
based on 
radiological 
features 
Hunter  
et al., 
199673 
USA 
UK 
Australia 
Chest 
Circumference 
height 
Follow-up visits by 
the same 
examiner, request 
for volunteers or 
conventions of 
LPA 
365 individuals 
936 measurements; 
497 concurrent 
height + chest 
circumference 
measurements 
Sex-specific mean ±2 SD 
references for chest, 0-7 yrs, 0-2 
yrs and 46-108 cm height (charts 
only) 
 
 
Hunter  
et al., 
199674 
USA 
UK 
Australia 
Canada 
Weight 
Height 
Sitting height 
Skinfold 
thickness 
(scapular, 
abdominal, 
triceps 
Extracts from 
hospital files, 
personal 
interviews 
409 individuals 
1,147 measurements  
516 male/ 631 female 
Sex-specific mean ±1 SD 
references for weight, 44-144 cm 
height, mean ±2 SD weight for 44-
104 cm height, mean ±2 SD 
weight for 104-146 cm height 
(charts only) 
Correlation weight and height 
versus several indices of body fat 
at different age groups (table) 
Mean skinfold thickness (scapular, 
abdominal, triceps), 18-20+ yrs 
(chart only) 
Rohrer Index, 6-18 yrs (chart only) 
Quetelet Index, 27-72 months 
(chart only) 
3 extreme 
obese 
individuals 
were excluded 
from the 
analysis 
Tachi- 
bana 
et al., 
199775 
Japan Height 
Height velocity 
National survey & 
repeated height 
records 
64 males/ 71 females 
measurements per 
age group males/ 
females: 
Sex-specific mean ±2 SD 
references for height and height 
velocity, 0-18 yrs (charts only) 
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Study 
Sample 
origin 
Variables 
collected 
Setting of data 
collection 
Sample size and 
data collection 
period 
Presentation of results Comment 
height:3-51/ 3-55 
height velocity: 3-47/ 
3-50 
Sex-specific mean for height, 0-
17.75 yrs (table) 
Hoover-
Fong  
et al., 
200776 
USA Weight 
Length/ height 
Head 
circumference 
Upper/ lower 
body segments 
Arm span 
Inner/ outer 
canthal 
distance 
Chest 
circumference 
Hand length 
Middle digit 
length 
Data extracted 
from clinical 
records of 
patients seen by 
one of the authors 
(CI Scott) at Al 
DuPont Hospital 
for Children 1967-
2004 
 
301 of 334 children 
1,964 weight 
measurements 
Sex-specific P5-P95 curves for 
weight, 0-36 mo and 2-16 yrs 
(charts only) 
Diagnosis 
made by one 
observer by 
clinical, 
radiographic 
and/or 
molecular 
means 
Hoover-
Fong  
et al., 
200877 
USA BMI 
Height 
Weight 
Upper to lower 
Body segment 
ratio 
Height velocity 
Longitudinal data 
extractions from 
clinical records of 
patients seen by 
one of the authors 
(CI Scott) at Al 
DuPont Hospital 
for Children 1967-
2004 
155 males/ 125 
females 
number of 
measurements 
males/ females: BMI: 
937/ 870, height: 
1,018/ 937, weight: 
960/ 893, upper/ 
lower ratio: 629/ 584, 
height velocity: 
764/752 
Sex-specific P5-P95 curves for 
BMI, weight, height and height 
velocity, 0-16 yrs (chart only) 
P5-P95 curves for upper/lower 
segment ratio, 2-16 yrs (chart 
only) 
 
del Pino 
et al., 
201178 
Argen-
tina 
Height 
Weight 
Head 
circumference 
Measurements 
made by the 
same observer 
during 1992-2009, 
Department of 
Growth and 
Development, 
Garrahan Hospital 
114 males/ 114 
females 
number of 
measurements 
males/ females: 
height: 867/ 908, 
weight: 863/ 935, 
head circumference: 
481/ 567 
Sex-specific P3-P97 references 
for height, 0-18 yrs, weight, 0-17 
yrs, head circumference, 0-6 yrs 
(charts and LMS tables) 
Diagnosis 
based on clinic 
and X-ray 
criteria; 
molecular proof 
in 67/228 cases 
Exclusion: 
chronic 
disease, shunt, 
leg-lengthening 
Hoover-
Fong  
et al., 
201779 
USA Height Mixed longitudinal 
data abstracted 
from medical 
records from a 
single clinical 
practice (CI Scott) 
162 males/131 
females with 1,005/ 
932 measurements 
Sex-specific P5-P95 chart, 0-36 
mo and 2-16 yrs 
Tables for mean and SD per 
month 
 
Tofts  
et al., 
201780 
Australia Height 
Weight 
Head 
circumference, 
BMI 
Measurements 
from clinical visits 
retrospectively 
extracted from the 
electronic medical 
records 1970- 
2015 
 
69 males/ females 
3,352 data points 
Sex-specific P10-P90 chart, 0-18 
yrs for height, weight, head 
circumference and BMI (chart 
only) 
Age corrected 
for prematurity 
Excluded from 
weight and BMI 
analysis if 
clinical 
diagnosis of 
overweight 
del Pino 
et al., 
201881 
Argen-
tina 
Sitting height 
Leg length 
Sitting height/ 
height 
Sitting height/ 
leg length 
Head 
circumference/ 
height 
Measurements 
made by the 
same observer at 
growth clinic 
1992-2016, 
Growth and 
Development 
department in 
Garrahan Hospital 
171 males/ 171 
females with 1,379/ 
1356 measurements 
Sex-specific P3-97 references for 
sitting height, leg length, sitting 
height/ leg length, sitting height/ 
height, head circumference/ 
height ratio, 0-21 yrs (charts and 
LMS tables) 
Diagnosis 
made on the 
basis of clinical 
examination 
and X-ray 
criteria; 
molecular 
testing 163/ 
342 
Hypochondroplasia 
Wynne-
Davies  
et al., 
198172 
UK Height 
Arm span 
Data related to 
head to pubis, 
pubis to heel 
Visits traced from 
records of 8 
hospitals 
24 individuals Height for age scatter plot on 
height reference of normal and 
achondroplasia population (chart 
only) 
Span for age scatter plot on 
reference of general population 
(chart only) 
Diagnosis 
based on 
radiographs 
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Study 
Sample 
origin 
Variables 
collected 
Setting of data 
collection 
Sample size and 
data collection 
period 
Presentation of results Comment 
Head to pubis and pubis to heel 
for age scatter plot on reference of 
general population (chart only) 
Appan  
et al., 
199082 
UK Height 
Sitting height 
Subischial leg 
length 
Pubertal onset 
Seen between 
1974 and 1988 in 
the Middlesex 
hospital, London  
56 males/ 28 females 
18 individuals were 
seen only once, 66 
twice or more often 
Sex-specific mean and SD for 
height velocity, 2.5-17.5yrs 
Diagnosis 
made on 
clinical and 
radiological 
criteria 
Grigeli- 
oniene  
et al., 
200083 
Sweden Height 
Sitting 
Height/height 
Arm span 
Head 
circumference 
Referred to 
Karolinska 
Hospital for 
disproportional 
short stature and 
radiological 
features 
12 males/ 11 females Comparison of body proportions 
(height, sitting height/height, arm 
span and head circumference) in 
SDS, p.Asn540Lys vs. no 
mutation (chart only) 
Presence of at 
least 3 
radiological 
features based 
on criteria by 
Hall and 
Spranger 
Pinto  
et al., 
201484 
France Height 
Weight 
Followed at the 
Bone Dysplasia 
Center of Necker 
Enfants-Malades 
Hospital 
22 males/ 18 females 
without growth 
hormone treatment 
Sex-specific mean and SD for 
height velocity, 4-18yrs (table) 
Sex-specific mean curve for 
height, sitting height, subischial 
leg length, 3-18yrs (boys)/ 2-13yrs 
girls (charts only) 
Diagnosis 
based on 
radiographs 
Acromesomelic dysplasia type Maroteaux, AMDM 
Langer 
et al., 
197785 
USA Height 
Weight 
Head 
circumference 
Arm span 
Upper/lower 
segment 
 6 males/ 4 females 
(2 males/ 7 females 
in previous literature) 
Case report - clinical data (partly 
longitudinal)  
ages varying from 0 to 35 yrs 
Diagnosis 
based on 
radiographs 
Khan  
et al., 
201286 
Pakistan Height 
 
 9 males/ 7 females Case report - clinical data of 6 
consanguineous Pakistani families 
ages varying from 9 to 38 yrs 
Diagnosis 
based on 
radiographs 
and mutation 
analysis of 
NPR2 
Sriva- 
stave 
et al., 
201687 
India Height 
Weight 
Head 
circumference 
 4 males/ 1 female Case report - clinical data of a 
consanguineous Indian family 
ages varying from 1 to 7 yrs 
Diagnosis 
based on 
radiographs 
and mutation 
analysis of 
NPR2 
Wang 
et al., 
201688 
Korea Height 
Arm span 
 3 males Case report - clinical data of 3 
boys from non-consanguineous 
Korean families 
Diagnosis 
based on 
radiographs 
and mutation 
analysis of 
NPR2 
Pseudoachondroplasia, PSACH 
Dennis 
and 
Renton, 
197489 
UK Height 
Weight 
Head 
circumference 
Upper segment 
lower segment 
Arm span 
Referred to 
Hospital for sick 
children, London 
1 male/ 3 females Case report - clinical data of four 
siblings  
ages varying from 3 to 10 yrs 
Diagnosis 
based on 
radiographs 
Hesel-
son  
et al., 
197790 
South 
Africa 
Height 
Arm span 
Investigated at 
Groote Schuur 
hospital and Cape 
Town university 
7 males/ 6 females Case report - clinical data of 13 
individuals  
ages varying from 3 to 30 years 
Diagnosis 
based on 
radiographs at 
ages 2-11yrs 
Horton  
et al., 
198291 
USA Height Records at 
genetic clinics of 
medical 
institutions in 
Kansas City, 
Seattle, Houston, 
Baltimore and 
Torrance 
28 males/ 33 females Mean ±1 SD references for height, 
0-18 yrs (chart and table) 
Inclusion based 
on strict clinical 
and radiological 
criteria 
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Study 
Sample 
origin 
Variables 
collected 
Setting of data 
collection 
Sample size and 
data collection 
period 
Presentation of results Comment 
Wynee-
Davies et 
al., 
198692 
UK Height 
Span 
Upper/lower 
segment 
Ascertained 
through 7 skeletal 
dysplasia and 
genetic centres 
Personal 
examination and 
clinical records in 
some cases 
20 males/ 12 females Description of stature and body 
proportions and other clinical 
features 
Height of familial cases on growth 
curves from Horton et al., 1982 
 
Mc-
Keand  
et al., 
199693 
USA Height Ascertained 
through University 
of Texas Medical 
Genetics patient 
population and  
supporting 
organisation LPA 
Questionnaires 
(transcribed from 
original data and 
phone contact) 
33 males/ 44 females Description of demography, family 
history, body measurements, 
skeletal complication, skeletal 
operations, general health 
problems, chronic conditions later 
in life, reproduction and social 
status 
Diagnosis 
made by 
medical 
geneticist 
and/or a 
radiologist 
specialising in 
skeletal 
dysplasias 
Song  
et al., 
200494 
Korea Height 
Arm span 
Limb height 
Trunk height 
Tibia/femur 
Radius/ 
Humerus 
 5 males/ 7 females Case report - clinical data of 12 
individuals 
ages varying from 3 to 36 years 
Diagnosis 
made by 
orthopedic 
surgeons and 
pediatric 
radiologists 
based on 
clinical/ 
radiological 
features and 
mutation 
analysis of 
COMP 
Yu  
et al., 
201695 
China Height 
Arm span 
Upper/lower 
segment 
Visits at Sixth 
People’s Hospital 
4 males/ 2 females Case report - clinical data of 6 
individuals 
ages varying from 3 to 20 years 
Diagnosis 
made by 
radiographic 
observations 
and mutation 
analysis of 
COMP 
Tariq  
et al., 
201796 
Pakistan Height  9 males/ 8 females Case report - clinical data of 4 
generation consanguineous family 
Diagnosis 
made by 
radiographic 
observations 
and mutation 
analysis of 
COMP 
Multiple Epiphyseal Dysplasia, MED 
Haga  
et al., 
199897 
Japan Height 
Long bone 
epiphyses and 
spine 
Metacarpo-
phalangeal 
length 
Followed at 
Shizuoka 
Children’s 
Hospital, National 
Rehabilitation 
Center for 
Disabled Children 
and University of 
Tokyo 
8 males/ 7 females Individual’s height, 0-18 yrs in 
males and females (charts, table) 
Metacarpophalangeal length: 
individual’s SDS for distal 
phalanx, middle phalanx, prox. 
phalanx and metacarpals (table) 
Plots of epiphyseal height versus 
metaphyseal at >4yrs   
Diagnosis 
criteria: 
irregular 
epiphyseal 
growth or 
deformity in >2 
epiphyses in 
the long bones, 
little or no 
spinal 
involvement, 
normal 
intelligence, 
normal facial 
appearance 
Seo  
et al., 
201498 
Korea Height Review of medical 
records (first 
presentation and 
latest follow-up) 
95 individuals Average height (z-score) in 
MATN3 and COMP 
 
MATN3, COMP 
mutation 
molecularly 
confirmed 
Diastrophic dysplasia, DTD 
Horton  
et al., 
198291 
USA Height Records at 
genetic clinics of 
medical 
institutions in 
38 males/ 34 females Mean ±1 SD references for height, 
sexes combined, 0-18 yrs (chart 
and table) 
Inclusion based 
on strict clinical 
and radiological 
criteria 
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Study 
Sample 
origin 
Variables 
collected 
Setting of data 
collection 
Sample size and 
data collection 
period 
Presentation of results Comment 
Kansas City, 
Seattle, Houston, 
Baltimore and 
Torrance 
Mäkitie 
and 
Kaitila, 
199799 
Finland Height 
Relative weight 
Weight for 
height 
Head 
circumference 
 
 
Referrals to the 
Children’s 
Hospital or 
Genetic Clinic in 
Helsinki 
Birth records, 
child health 
centre, schools 
and hospitals 
 
53 males/ and 68 
females 
104 families 
 
Sex-specific P10-P90 references 
for height, 0-20 yrs (chart and 
table) 
Sex-specific P10-P90 references 
for weight, 60-145/135 cm height 
(table) 
Sex-specific relative height, 0-20 
yrs (chart) 
Sex-specific P25-P75 references 
for relative weight, 60-150/140 cm 
height & 10-60/45 kg weight 
(boys/girls) (chart) 
Correlation to relative adult height 
at birth, 1yr and 5 years 
Assessment of intrafamilial 
variability 
Pubertal growth component 
evaluation based on the Infancy 
Childhood Puberty (ICP) model 
Diagnosis 
based on 
clinical 
features, 
radiological 
findings and 
family history 
Barbosa 
et al., 
2010100 
Portugal Height Referrals to 
Medical Genetics 
Services after 
screening in 4 
main Portuguese 
Services of 
Medical Genetics 
and 4 
Orthopaedics 
Services 
8 DTD, 4 rMED and 2 
mDTD (mild DTD, 
intermediate 
phenotype between 
DTD and rMED) 
All SLC26A2 positive 
Height position of each individual 
relative to Finnish DTD reference; 
e.g. <10th centile 
Diagnosis 
made based on 
clinical protocol, 
photos and X-
rays 
Cartilage Hair Hypoplasia, CHH 
Mäkitie et 
al., 
1992101 
Finland Height 
Sitting height 
Weight 
Head 
circumference 
Arm span 
At visits Children’s 
Hospital, Helsinki 
Birth records, 
child health 
centres, schools 
and hospitals 
44 males/ 56 females 
81 families; 17 
families incl two or 
three affected 
siblings  
Sex-specific P10-P90 references 
for height, weight and sitting 
height, 0-20 yrs (chart and table) 
Median relative height, 0-20 yrs 
(chart) 
Sex-specific P25-P75 references 
for relative weight, 60-130 cm 
height & 10-45 kg weight (chart) 
Relative sitting height for adult 
height SDS (chart) 
Median relative sitting height and 
subischial leg length, 0-20yrs 
(chart) 
Pubertal growth component 
evaluation based on ICP model 
Diagnosis 
based on 
radiological and 
clinical criteria. 
Spondyloepiphyseal dysplasia congenita, SEDC and other phenotypes of COL2A1 mutations 
Horton  
et al., 
198291 
USA Height Records at 
genetic clinics of 
medical 
institutions in 
Kansas City, 
Seattle, Houston, 
Baltimore and 
Torrance 
34 males and 28 
females 
Mean ±1 SD references for height, 
0-18 yrs (chart and table) 
Inclusion based 
on strict clinical 
and radiological 
criteria 
Nishi-
mura  
et al., 
2005102 
Japan Height Medical records 
and 
questionnaires 
completed by 
physicians 
COL2A1 mutation in 
32 males and 26 
females of  
77 individuals with 
radiological fit of 
known COL2A1 
phenotype 
A list of birth details (weight and 
length, gestational age), height 
and age at examination and 
height/ arm span ratio for all 
individuals with COL2A1 mutation 
Based on 
radiological 
criteria, clinical 
phenotypes 
were divided 
into SED 
spectrum, 
Kniest, Stickler 
dysplasia type I 
and 
uncommon/ 
atypical type II 
collagenpathies 
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Study 
Sample 
origin 
Variables 
collected 
Setting of data 
collection 
Sample size and 
data collection 
period 
Presentation of results Comment 
Terhal  
et al., 
201268 
Europe 
Australia 
Lebanon 
Israel 
South 
America 
Height 
Weight 
Head 
circumference 
Recruitment 
through two 
laboratories that 
offer DNA 
analysis of 
COL2A1 gene 
Standard checklist 
filled in by 
referring physician 
and growth curve 
33 males/ 46 female 
381 height 
measurements with 
glycine substitutions 
 
27 children with other 
mutations in COL2A1 
gene  
96 height 
measurements 
M ±1.6 SD references for height, 
0-20 yrs based on data from 
individuals with glycine 
substitutions (only chart) 
 
Exclusion 
criteria: 
individuals with 
loss-of-function 
mutations, with 
perinatally 
lethal 
phenotype, with 
developmental 
disability, 
severe birth 
asphyxia, 
abnormal 
karyotype, with 
growth 
hormone 
treatment, who 
were born <30 
weeks GA, or 
measurements 
<2 yrs of age if 
born <36 
weeks GA 
Léri-Weill Dyschondrosteosis, LWD – SHOX-deficiency 
Ross  
et al., 
2001103 
USA Height 
Lower segment 
Arm span 
Forearm length 
Pubertal 
development 
Age of 
menarche 
Metacarpal-
phalangeal 
profiles 
Radial length 
Subjects referred 
for short stature or 
Madelung 
deformity 
11 males/ 32 females Individual age, height SDS, 
upper/lower segment SDS; arms 
span SDS and right radius SDS 
(table) 
Height SDS scatter plot, 0-60 yrs 
(chart) 
No GH 
treatment 
Ross  
et al., 
2005104 
USA Height 
Lower segment 
Arm span 
Forearm length 
Arm/ leg 
circumference 
Pubertal 
development 
Bone age 
Clinic subjects 
referred for short 
stature or LWD in 
a parent  
14 males/ 20 females 
with age range 1 to 
10 yrs 
Sex-specific mean ±SD for age, 
bone age, height SDS, weight 
SDS, BMI SDS, head 
circumference SDS, Arm span 
SDS, arm span-height (cm) and 
upper segment/lower segment 
(table for cohort) 
Individual clinical data incl age, 
bone age, height SDS, upper 
segment/lower segment and arm 
span SDS (table) 
Only LWD 
individuals with 
confirmed 
SHOX 
abnormalities, 
none with 
growth 
hormone 
treatment 
Salmon-
Musial  
et al., 
2011105 
France Height 
Parental height 
Sitting height 
Length/ 
circumference 
of upper and 
lower segment 
Medical records 
for children 
enrolled in the 
Department of 
Pediatric 
Endocrinolgy of 
the University 
Hospital in Lyon 
8 males/ 14 females 
from 18 families 
  
Osteogenesis Imperfecta, OI 
Vetter  
et al., 
1992106 
Germany 
Austria 
Switzer-
land 
Italy 
Turkey 
Height 
Motor 
performance 
IGF-I 
Seen at 1-year 
interval for clinical 
evaluation 
127 patients with 
types I, III and IV OI 
P5-P95 height references, 0-10 
yrs for type I, III and IV OI (charts 
only) 
P5-P95 weight references, 0-10 
yrs for type I, III and IV OI (charts 
only) 
Median IGF-I serum 
concentrations per age group 1-2 
yrs, 2-6 yrs, 6-8yrs, 8-10yrs and 
OI type 
Summary of incidence of several 
extraskeletal symptoms in ages 1-
4yrs and 5-10 yrs OI type 
Diagnosed in 
the first two 
years of life 
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Study 
Sample 
origin 
Variables 
collected 
Setting of data 
collection 
Sample size and 
data collection 
period 
Presentation of results Comment 
Lund  
et al., 
1999107 
Denmark Height 
Sitting height 
Arm span 
Subischial leg 
length 
Weight 
Head 
circumference 
IGF-I 
IGFBP-3 
Referred to the 
department of 
clinical genetics at 
Rigshospitalet in 
Copenhagen 
Mean of 3 
repeated 
measurements 
 
42 males/ 44 females 
with types I, III and IV 
OI  
Scatter plots for height SDS, head 
circumference SDS, height SDS-
mean unaffected family member 
SDS, subischial leg length SDS-
sitting height SDS, arm 
span/height ratio 0-70yrs and IGF-
I SDS, 2-10yrs (charts) 
Height SDS, difference to target 
height SDS and unaffected family 
members SDS, IGF-I SDS, 
IGFBP-3 SDS, arm span SDS, 
arm span/ height ratio, subischial 
leg length SDS-sitting height SDS, 
head circumference SDS, 
difference head circumference 
SDS and height SDS per OI type, 
per collagen type defect 
(quantitative or qualitative) for 
children and adults respectively 
(tables) 
Exclusions: 
patients with 
non-OI bone 
disorder, liver 
disease, 
endocrine 
disorder 
OI according to 
Sillence 
characterisation 
Zeitlin  
et al., 
2003108 
Canada Height 
Weight 
(areal)BMD 
At the Shriners 
Hospital for 
Children in 
Montréal, Canada 
during 1992 and 
2001 
125 OI patients that 
were treated with 
cyclical intravenous 
pamidronate  
Mean ±SD for entire study 
population, 1yr and 4 yrs 
treatment group per type OI 
(table) 
Mean ±SD at start of treatment 
and after 1yr of treatment per type 
OI (table) 
Scatter plot incl regression line for 
height for age, 0-20 years per OI 
type (chart and equation) 
Height for age regression line and 
scatter plots of individuals with at 
least 4yrs pamidronate treatment, 
0-20 yrs per OI type and sex 
(chart only) 
Final height after treatment 
(individual data) 
 
Engel-
bert  
et al., 
2004109 
Nether-
lands 
Height 
Weight 
Head 
circumference, 
Sitting height 
Leg 
length/sitting 
height ratio 
Followed in the 
Dutch national 
centre for 
diagnosis and 
treatment of 
children with OI 
between 1996 
and 2000 
49 children, none 
treated with 
bisphosphonates 
Mean ±SD at start and end of 
study for height, weight, head 
circumference, sitting height, leg 
length/ sitting height ratio per OI 
type 
 
 
Aglan  
et al., 
2012110 
Egypt Height 
Weight 
Head 
circumference 
Arm span 
Sitting height 
Recruitment from 
limb 
malformations 
and skeletal 
dysplasia clinic 
(LMSDC), Medical 
Services Unit, 
NRC 
55 males/ 69 females 
before initiation of 
bisphosphonate 
treatment 
 
Scatter plot height SDS, 0-22 yrs 
(chart only) 
Scatter plot weight SDS, 0-22 yrs 
(chart only) 
Scatter plot head circumference/ 
height ratio SDS, 0-22 yrs (chart 
only) 
Clinical and 
radiological 
evaluation to 
determine 
Sillence type 
Germain-
Lee  
et al., 
2016111 
USA Height or arm 
span 
Weight 
Height velocity 
Medical records of 
patients who were 
seen in OI Clinic 
at Kennedy 
Krieger Institute 
from 2004 to 2013 
144 children and 199 
adults in OI type I, III, 
IV and V 
Mean for height SDS in children 
and adult per IO type (chart and 
table incl range) 
Mean for height SDS in children 
<11yrs and >11-20yrs (chart and 
table incl range) 
Scatter plot for height, 0-20yrs 
(individual series) in children with 
type I and III OI (chart only) 
Scatter plot for weight, 40-200cm 
height (individual series) in 
children with type I, III and IV OI 
(chart only) 
OI according to 
Sillence 
characterisation
, type V 
according to 
Glorieux 
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1.5 A GROWTH CHART AS A MATRIX 
Keeping in mind the differences between references based on cross-sectional and longitudinal 
data, no child can be expected to follow a specific centile or SD postion112,113 but rather its 
own growth curve.114 A catch-up/ catch-down in length during the first two years of life is 
reported for more than 50 percent of normal infants.115,116 In older ages, a catch-up can follow 
periods of restricted growth.114 Centile crossings is also a common phenomenon.116,117 
Evaluations of individual height series in the First Zürich Longitudinal Growth Study showed 
little evidence that a child strictly follows a certain centile.117 Differences between a child’s 
maximum and minimum height SDS were calculated to define his/her growth channel. In 
about 2/3 of children this covered more than one SDS and only 1/4 kept within a growth 
channel of less than 0.5 SDS during prepubertal ages.117 
Differences in tempi are most apparent during pubertal ages but a child can be expected to 
crosses centiles already during childhood if s/he is an early or late mature.115 The child’s size 
at a given time point is thus not necessarily always of most interest, but rather the changes in 
size over ages, i.e. the growth pattern.33 
1.6 ILLUSTRATING GROWTH POSITION CHANGES OVER TIME 
As noted earlier in section 1.3.4, centile curves are not meaningful when expressing changes 
in a child’s height position over time.33,53 Using SDS scales, on the other hand, changes can 
be compared over ages118 and also allows comparison of several anthropometric variables. 
For instance, Figure 9a summarises weight, length and BMI development in the girl 
previously illustrated in the Swedish growth chart (Figure 7). Similarly, a closer look at the 
effect of growth hormone treatment in a boy with hypochondroplasia, Figure 9b, suggests a 
temporary height gain from improved sitting height position rather than from leg length. 
 
Figure 9 SDS charts to illustrate development of several anthropometric variables: (a) height, weight and BMI 
development in the girl shown in the growth chart in Figure 7 and (b) sitting height and leg length SDS in a GH-
treated boy with hypochondroplasia. 
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1.6.1 Turner syndrome as an example 
This SDS presentation is thus valuable to capture progression and magnitude of positional 
changes, which also allows comparison between cohorts.118 Height in girls with Turner 
syndrome from different ethnic background follows the same pattern but differs in absolute 
height (Figure 10a). Growth might thus be similar in girls with Turner syndrome when taking 
into account differences in height of the respective background population. Ethnic differences 
strongly influence adult height in girls with Turner syndrome, which generally is 20 cm lower 
than the background population mean.119 
Similarly, comparing height development in Turner syndrome to girls with idiopathic short 
stature (ISS) indicates that tempo in both short stature conditions might be different, Figure 
10b. Both groups improve height position towards the end of the growth period since the 
background population reaches final height earlier. Final height position in girls with ISS 
from this reference and in whom pubertal growth is not compromised by ovarian failure is 
about -2.7 SDS with temporary position of -3.6 SDS due to decreased growth tempo. 
Spontaneous growth in Turner syndrome has been described by several authors; for review 
see Bertapelli et al.,65 most recent studies also including girls with hormone treatment.65 
Spontaneous puberty is reported for only 10-17 percent,120,121 thus leaving the majority of 
girls with Turner syndrome without pubertal growth spurt and prolonged growth period.122 In 
those, only 96 percent of final height is achieved at 16 years of age.25,121,123 Adult height in 
those with and without spontaneous puberty is, however, the same.121 
 
Figure 10 Height SDS (a) in girls with Turner syndrome from Northern Europe124 (red), Argentina125 (yellow) and 
Japan126 (blue) relative to WHO reference37,45 and (b) in girls with Turner syndrome124 (red) compared to with 
idiopathic short stature (ISS, purple)127 expressed relative to Dutch reference.14 
A closer look at body proportions in Turner syndrome suggests that leg length is more 
severely affected than sitting height (Figure 11). Tempo of leg length growth seems to be 
slower compared to children of normal height, which might explain the improvement of leg 
length position after 13 years of age when legs of normal girls have achieved final size. A 
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pubertal spurt in height and sitting height is not observed. Height position is temporarily 
compromised during pubertal ages but sitting height (and thus height) improves after 17 years 
of age. Note, however, that the cohort in the illustrated example was treated with estrogen, 
which could also stimulate the late catch-up. 
 
Figure 11 Development of height, sitting height and leg length in non-GH treated girls with Turner syndrome124,128:  
(a) as yearly increments and (b) as SDS relative to Dutch normal reference.7,14 Note that this cohort was treated with 
estrogen. 
Skeletal phenotype in Turner syndrome includes short stature with mild body disproportion 
due to short legs, cubitus valgus and aberrant facial morphology. It has been suggested that 
except for SHOX haploinsufficiency, deficiency of the proteoglycan biglycan is connected to 
a skeletal phenotype and is also responsible for vascular/ cardiac symptoms that are typical in 
Turner syndrome.129 Biglycan is functional for extracellular matrix assembly and 
maintenance, interacting with collagen type I, II, III and IV and seems also to regulate TGF-
beta and BMP4 activities.130 The expression level of biglycan as determined by number of X-
chromosomes is clearly related to height with short stature with short legs in Turner 
syndrome and tall stature with long legs in triple X syndrome.131 In contrast to Léri-Weill 
dyschondrosteosis (LWD), also having SHOX deficiency, Madelung deformity is rarely seen 
in Turner syndrome and facial phenotype, including mouth anatomy, is usually normal in 
LWD. In addition, arm span is normal for height in girls with Turner syndrome132 but shows 
substantial deficit in LWD.133 
1.6.2 The importance of SD 
A position in the growth chart can easily be calculated by z = (Measurement-Mean)/SD for 
the same age in the reference material given that the variable follows a normal distribution.8 
For measures such as weight and BMI, where skewness has to be accounted for, LMS values, 
introduced in section 1.3.3, can be used. SDS can then be calculated by z = 
((Measurement/M)L-1 )/LS, which is z =(Measurement-M)/MS if L=1.8 
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The SDS value is thus influenced by the mean value of the reference material and especially 
the size of the SD. As noted earlier in section 1.3.1, variability during pubertal ages may be 
lower in longitudinal references since differences in tempo and pubertal timing can be 
adjusted. The effect of this adjustment on the SD can be seen in Figure 12a. In other words, a 
great deal of variability during pubertal ages is related to tempo, which cannot be accounted 
for in cross-sectional studies but which influences calculation of SDS position. SD 
development in the normal population references used in this PhD project are therefore 
shown in Figure 12b-d. The size of SD in the Swedish growth charts134 is modified while 
references from the WHO,37 the fourth Dutch nation-wide survey14 and the UK135 are clearly 
based on cross-sectional data. Nevertheless, it is crucial to note that SDS during pubertal ages 
per se can be misleading136 since comparisons are based on chronological ages. These are, 
however, a poor proxy for biological age during pubertal ages, as seen earlier in Figure 3. 
 
Figure 12 Development of SD for height in boys (blue) and girls (red): (a) differences in SD if conditional 
(longitudinal, dashed) versus unconditional for tempo (cross-sectional, line) in traditional British height 
references;34,35 (b) differences in Swedish height reference134 with SD1 referring to empirical SD and SD4 referring to 
SD used in growth charts; (c-d) SD in WHO (WHO),37 national British (UK90)135 and Dutch (NL96)14 references. 
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Similarly, average size of the reference material influences resulting SDS value. The 
observant reader might have noticed that height position of the Northern European Turner 
reference (marked in red) in Figure 10a does not match the same illustration in Figure 10b. 
This is because the curves are based on different background populations. The WHO 
reference37,45 seems suitable for comparing different ethnical groups of the same condition 
while a Dutch reference14 might be more meaningful for comparing two short stature 
conditions from the same background population. 
1.7 GROWTH PROMOTING THERAPY 
Orthopedic limb lengthening may be a common procedure for increasing height in extreme 
short stature. It is no standard treatment in children with achondroplasia in Sweden and 
Northern Europe but is commonly used in Southern Europe (Florian Innig, BKMF, personal 
communication 2018). This surgical procedure is, however, tedious and not necessarily 
without complications.137 Height gain of 20 cm might be achieved.138 
Growth hormone treatment (GH Rx) often has modest effects in most severe short stature 
skeletal dysplasias139 including achondroplasia.140 Reports on adult height are limited to one 
study from a small Japanese sample with achondroplasia (8 boys/ 14 girls) where height gain 
from GH Rx alone was less than 4 cm. Short-term height gain of 0.5 SDS141 and 0.6/0.8 
SDS142 have also been reported, with141 and without142 changes in body proportions. 
Future therapies for achondroplasia may target FGFR3 signalling and non-FGF signalling 
pathways.143 These include soluble FGFR3 that bind and sequester FGF ligand, anti-FGFR3 
antibodies that block ligand binding to the receptor and subsequent downstreaming signalling 
pathways, tyrosine kinase inhibitors and CNP or CNP analogues that antagonize and inhibit 
FGFR3 downstreaming signalling.143 
Growth promoting therapy in milder short stature conditions, such as Turner syndrome, still 
focuses on GH Rx. Adult height is typically increased by roughly 7 cm,144 or using 
supraphysiologic doses almost double.145 Benefits from GH Rx in Turner syndrome is similar 
to ISS, SGA and SHOX deficiency.146 Clinical practice nowadays shifts towards starting GH 
Rx at earlier ages and less severe height position147 and clinical guidelines for girls with 
Turner syndrome suggest GH Rx to be initiated at “about 4 to 6 years and preferable before 
13 years, if growth is poor or is likely to be compromised.”148 Treatment response is, 
however, variable and unpredictable,149 which makes it difficult for pediatric endocrinologists 
to communicate realistic treatment outcomes to patients and their families. 
In summary, detailed descriptions of growth and body proportions development from birth to 
adulthood is valuable as background for any growth promoting intervention. Similarly, 
evaluation of growth promoting therapy using growth charts can support clinical decisions 
and facilitate communication with families. 
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2 AIMS 
The aim of this study was to construct auxological tools for following growth in children with 
extreme and/ or disproportional short stature and to evaluate medical intervention that 
promotes growth. 
More specifically, 
 Growth in achondroplasia: 
To construct sex- and age specific growth references for height, weight, head 
circumference and body mass index and to discuss the development of these 
anthropometric variables in an European achondroplasia cohort. 
 
 Body proportions in achondroplasia: 
To construct sex- and age specific references for sitting height, leg length, arm span and 
foot length and to discuss the development of body proportions in achondroplasia. 
 
 Growth in other skeletal dysplasia resulting in extreme short stature: 
To describe the growth pattern of individuals with skeletal dysplasia and extreme short 
stature in the achondroplasia growth charts. 
 
 Evaluation of growth hormone therapy: 
To characterise girls with Turner syndrome with typically good and poor response in 
height. 
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3 MATERIALS AND METHODS 
The aim of this PhD project can be divided into two parts; one concentrating on growth and 
body proportion in children with skeletal dysplasias resulting in extreme short stature (Paper 
I-IV) and the other on evaluating GH Rx in girls with Turner syndrome (Paper V). The 
following sections will follow the same division. 
3.1 GROWTH AND BODY PROPORTION REFERENCES IN SEVERE SHORT 
STATURE 
The first part of this PhD project focuses on constructing references from a European 
achondroplasia cohort (Paper I-II), on implementing those as clinical charts (Paper III) and 
suggesting these for following children with other extreme short stature conditions (IV). 
3.1.1 Collecting data for achondroplasia and other short stature conditions 
Data from children with skeletal dysplasia including achondroplasia was collected by 
different means and sources. 
The majority of measurements were conducted by the same observer (LN) mainly during 
routine visits at the skeletal dysplasia clinic at the Department of Pediatrics at Karolinska 
University Hospital in Stockholm, Sweden, and at annual meetings of the German 
Association for People of Short Stature and their Families (Bundesverband Kleinwüchsige 
Menschen und ihre Familien e.V., BKMF). Measurements followed a standardised technique. 
Infants and young children were measured in supine position with legs extended and both 
heels against a moveable board. Stretched standing position was measured from 
approximately two years of age using a statiometer (Hyssna Measuring Equipment AB, 
Sweden) with the child looking straight ahead and back and heals against the wall. Sitting 
height was measured in a similar way with the same equipment; until about two years of age 
in supine position (i.e. as crown-rump length), and for older ages sitting straight on a stool, 
with back, buttocks and head against the wall looking straight ahead. Head was measured at 
its maximum circumference using a nondistensible tape. A calibrated digital scale was used 
to record weight of the child that was in light clothes. Arm span was determined as the 
longest distance between finger tips and was measured on the wall by two observers using 
stretching technique. Data series were retrospectively complemented with entries from birth, 
child health and school records. Additional measurements made by the same observer were 
available from an earlier study.142 
Data was also collected from colleagues in Denmark, Finland, Norway and Sweden and in 
collaboration with Sweden’s Association of Short stature (Föreningen för kortvuxna, DHR). 
Colleagues from Spain, Argentina and the USA contributed with measurements from 
children with short stature conditions other than achondroplasia that they followed in their 
skeletal dysplasia clinics. 
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Diagnosis was based on genetic and/or clinical and radiological investigation, which seemed 
sufficient for the achondroplasia cohort (Paper I-II). For analysing growth in other skeletal 
dysplasia (Paper IV), genetic confirmation was crucial for diagnosis, which is why we 
restricted the scope of this study to diagnoses with distinct radiological and clinical criteria. 
The following diagnoses were finally included: 
 Acromesomelic dysplasia type Maroteaux (AMDM): an autosomal recessive skeletal 
dysplasia. The inactivating mutations in NPR2, the gene encoding for the CNP 
receptor NBR-B disturb the counteracting balance between FGFR3 and NPR-B 
signalling. This allows for a dominance of FGFR3 activity making the development 
of height position in the achondroplasia chart fundamentally interesting. 
 Pseudoachondroplasia (PSACH): an autosomal dominant skeletal dysplasia caused by 
heterozygous mutations in the gene encoding cartilage oligomeric matrix protein 
(COMP). Height position progressively decreases after the first year of life resulting 
in an adult height within the achondroplasia range, thus making this unique growth 
pattern interesting. 
 Hypochondroplasia: an autosomal dominant skeletal dysplasia caused by mutation in 
the gene encoding for FGFR3, thus sharing the similar genetic background with 
achondroplasia. Note that several children with radiological/ clinical 
hypochondroplasia diagnoses are not linked to FGFR3,150 suggesting genetic 
heterogeneity. We therefore focused on those with genetically confirmed 
hypochondroplasia. 
3.1.2 Construction of achondroplasia references and growth charts 
All 4,375 measuring occasions were recorded and age, BMI, subischial leg length (SILL) and 
sitting height/ height ratio (SH/H) were calculated. Measurements from adults aged 20 to 40 
years were coded as 20 years of age. Individual data series were plotted for children with 
several visits to identify possible data entry or measuring errors. These were corrected if 
possible or excluded. Infant measurements were excluded for those born prematurely, i.e. 
before gestational week 37 (n=6). Additional exclusion criteria were growth-promoting 
therapy (n=51) such as leg lengthening (height, SILL, weight, BMI) or growth hormone (all 
measures) and other conditions affecting growth (n=4). Head circumference measurements 
from children with shunts were excluded (n=9). Measurements from individuals (n=28) with 
eight-plates151 applied for correcting/ preventing varus or valgus deformity of the legs were 
not excluded. 
Since the sample comprised a mix of cross-sectional and longitudinal data, we could not 
adjust individual data series for differences in tempo and to average age at peak height 
velocity, discussed in section 1.3.1. The data set was therefore treated as a cross-sectional 
cohort. The final data set was additionally trimmed for each child contributing only one 
measurement to pre-defined age groups; i.e. at birth, at one week and monthly thereafter until 
one year of age, bi-monthly for second year of life, quarterly until four years and yearly 
thereafter. This was done to avoid that individuals with extensive number of measuring 
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occasions contributed disproportionally to the fitted curves. Final number of data points for 
data analysis was for height 3,818, for weight 3,693, for head circumference 2,616, for BMI 
3,526, for sitting height 1,310, for leg length 1,272 and for arm span 1,148. Descriptive 
statistics for these pre-defined age groups were obtained as estimates of the empirical 
(measured) data that could be used for comparison to the fitted values. 
Sex-specific growth references were modelled in the GAMLSS51 package in R Studio version 
3.2.3, which includes the LMS method as special case.8 Model fit was evaluated based on 
QQ-plots and primarily on appearance of the fitted curves. 
 
Figure 13 Development of L, M and S curves in test models for determining model distribution for height in girls 
More specifically, test models were initially run to investigate the distribution of each 
anthropometric variable such as for height (Figure 13). These test runs comprised 
distributions of two parameters (i.e. normal distribution), three parameters (i.e. Box-Cox 
normal) and four parameters (i.e. Box-Cox power exponential),52 which were then compared 
based on versions of AIC and, visually, on fitted ±2 SD curves. Note that four parameter 
distribution models already seemed impractical for future use of the resulting references, 
since SDS calculation would be more complicated. 
 
Figure 14 Development of L, M and S curves in models searching for the final height model in girls 
Based on the best test run model, further models were fitted to determine a suitable final 
version that would represent empirical data but, at the same time, give a smooth curve. 
Increasing complexity of the model, i.e. higher edf values, was visually evaluated based on 
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appearance of resulting ±2 SD curve (Figure 15) keeping in mind model fit in terms of low 
information criterion (Table 3) and model diagnostics (Figure 16). 
Table 3 Summary of models and information criteria exemplifying model selection for height in girls 
 Information criterion 
edf transformed 
age  
 GAIC 
(#2) 
GAIC 
(#3) 
GAIC 
(#log(n))  L M S 
test runs 
  final model 10691.05 10709.05 10792.34 
0  
(fixed L=1) 
9 5 0.75 
  test 1 10729.09 10743.05 10807.64 0.1 7 0.1 0.5 
  test 2 10689.01 10715.22 10836.48 1 14 4 0.6 
Finding final model 
  final model 10691.05 10709.05 10792.34 
0  
(fixed L=1) 
9 5 0.75 
  more df M 10694.17 10718.18 10829.23 
0  
(fixed L=1) 
15 9 0.75 
  more df L 10689.77 10711.77 10813.56 2 9 5 0.75 
  less df S 10696.88 10711.88 10781.28 
0  
(fixed L=1) 
9 2 0.75 
Considering the small sample size, model selection based on a conservative SBC (GAIC 
(#log(n)) might be appropriate, yet on the other hand, the cross-sectional design, i.e. not 
having data for each individual at each age, might prefer a liberal criterion (GAIC(#2)). Note 
therefore that versions of GAIC were used as guidance for finding appropriate smoothness of 
the curve while final model selection was based on appearance. 
 
Figure 15 Resulting +2 SD curves for height models in Table 3. Note that +2 SD lines during infancy period are based 
on 3 months data for this illustration, thus not representing final curve pattern. 
All anthropometric variables besides weight and BMI were assumed to follow a normal 
distribution and were therefore fitted accordingly to a LMS model with constant L=1. For 
weight and BMI, all three LMS parameters were modelled for age. Note that, due to high 
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velocity in head circumference during infancy, more weight was given to the measurements 
during the first years of life, which was done by an age transformation of x=x0.35. 
 
Figure 16 Example of model diagnostics for final model in Table 3: residuals plotted against fitted values and age and 
normal QQ-plot. 
From the resulting references, changes between full chronological ages were calculated as 
proxy for growth velocity since the data was too limited to construct velocity references. 
These yearly increments give thus only an indication of velocity and were compared to 
equivalent estimates from other achondroplasia and normal population references. 
The clinical growth charts were technically constructed in collaboration with PC PAL, a 
medical software company with focus on growth modules for medical systems. 
3.1.3 Analysing growth and body proportions in short stature skeletal 
dysplasia 
Another focus of this PhD project was to provide insights into how height and body 
proportions develop with age in achondroplasia and other skeletal dysplasias with severe 
short stature. It was therefore natural to illustrate the progress of obtained reference values as 
well as individual patterns as SDS charts. Development of height could thus be compared to 
sitting height and leg length and also timing and magnitude of growth restriction could be 
described. 
The WHO reference37,45 was used for all comparisons of height. Since this material does not 
cover head circumference up to adult size nor body proportions, SDS for head circumference, 
sitting height and leg length was estimated from national British references.135,152 This 
seemed adequate since adult height both references is comparable. A weakness of the British 
body segment reference is that it is based on a rather small South-English sample and that 
subischial leg length was obtained from subtracting sitting height from previous height 
references.152 Furthermore, these do not cover sitting height/ height ratio and arm span, which 
had to be complemented by Dutch references.7,153 It is worthwhile noting that there is only 
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one reference,153 based on three cross-sectional surveys, with distribution parameters to 
calculate SDS for all growth and body proportion measures used in this study. Comparing 
sitting height/height ratio of this reference to values in the fourth Dutch nation-wide survey7 
showed surprising deviations and possible unreliable patterns. Furthermore, it could also be 
argued whether it is fair to compare extreme growth development to a reference from a very 
tall population. 
Growth and body proportion data for children with AMDM, PSACH and hypochondroplasia 
were also converted to SDS relative to the achondroplasia reference. Individual data series 
were illustrated as SDS chart and superimposed on the clinical achondroplasia chart. 
3.2 GROWTH HORMONE TREATMENT IN GIRLS WITH TURNER SYNDROME 
The second part of this PhD project focused on characterising good and poor response to 
growth hormone treatment (GH Rx) in girls with Turner syndrome, for which data was 
retrieved from the Swedish National Register for growth hormone treatment of children and 
adolescents. The register export covered details on treatment start and stop, on birth and 
parents, as well as visit specific data on height, weight, sitting height, pubertal stages, GH and 
other medication. 
Visit specific data was first coded for predefined milestones such as date at treatment start, 
first year follow-up, pubertal onset as Tanner breast stage >B1 and adult height. Both 
pubertal onset and adult height were evaluated based on individual data series to ensure that 
details of the selected visit were congruent with subsequent measurements. Adult height was 
defined as height velocity <1cm/ year during a minimum time interval of six months. Parental 
height was calculated as MPH SDS. 
SDS calculations were based on the Swedish reference134 for height and the Dutch references 
for sitting height, leg length and sitting height/ height ratio7. As noted in section 1.6, it might 
be misleading to calculate SDS during pubertal ages, which was, nevertheless, needed to 
obtain a height position at GH Rx start. On the other hand, the majority of girls with Turner 
syndrome lack spontaneous puberty and are therefore most often pre-pubertal at GH Rx start. 
The pre-pubertal height references in the Swedish growth chart were therefore expected to 
give a more realistic estimate of height positions during typically (for general population) 
pubertal ages. Tabled mean and SD values for this reference were therefore estimated from 
the growth chart. Height and age coordinates obtained using Adobe Illustrator were modelled 
by 2nd degree polynomial regression where R-squared was used as indicator for model fit. 
Treatment response was evaluated as total height gain from GH Rx estimated as delta height 
SDS from therapy start to adult height. Since defining poor response by arbitrary cut-offs, 
such as <0.5 SDS,154,155 could lack empirical background, we used the entire distribution of 
total height gain to define the different response groups, as seen in Figure 17. Five percent of 
values at each end of the distribution were considered as non-representative outliers and were 
thus excluded. The nearest 25 percent were chosen as typically high (good) and low (poor) 
responses leaving 40 percent in the middle representing “average” or intermediate response. 
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Note that resulting response groups were overlapping when summarised as histogram (in 
Figure 17). For instance delta height of 0.56 SDS could be classified as intermediate and as 
poor. Responses of the same size, 0.5 SDS defined as 0.375 to 0.625 SDS, were thus assigned 
to the same group (poor). Resulting number of observations in the good and poor group 
resulted therefore not exactly in 25 percent each. 
 
Figure 17 Distribution of total height gain SDS used to define good and poor response: (a) as cumulative percentages 
and (b) as histogram 
Variables previously suggested to be predictive for treatment success were summarised as 
descriptive statistics and as scatter plots, which were helpful to identify possible sub-groups. 
Special focus was thus given to: 
 MPH as indicator of familial height including the child’s deviation from it 
 Age and height position at GH Rx start 
 Initial treatment response defined as height gain from first treatment year 
 GH dose (µg/kg/day) at 12 months of treatment as proxy for dose 
 Age at pubertal start divided into those with spontaneous and with induced puberty 
In addition, simple SITAR-models were run for each of the response groups. Obtained 
average curve would illustrate the growth pattern of both response groups and model 
parameters could be used to compare differences in size, tempo and velocity. 
3.3 ETHICAL CONSIDERATIONS 
These studies were approved by the Regional Ethical Review Board at Karolinska Institutet, 
Stockholm, Sweden. The board of the Swedish National Register for growth hormone 
treatment of children and adolescents also approved the project on evaluating good and poor 
response to growth hormone treatment. 
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4 RESULTS AND DISCUSSION 
This section will discuss selected findings of both parts of this PhD project; i.e. growth and 
body proportions in extreme short stature (Paper I-IV) and response to GH Rx in Turner 
syndrome (Paper V). Some challenges in this kind of auxological studies are also touched 
upon. 
4.1 GROWTH AND BODY PROPORTIONS IN ACHONDROPLASIA 
Achondroplasia-specific references are available from various ethnical groups and 
geographic regions (see Table 2), which makes it possible to study variation and possible 
effect of background populations on height. A description of the growth pattern including 
ages when growth position is compromised (i.e. timing) and how much growth position is 
lost (i.e. magnitude) is generally missing. Existing evaluations of height in achondroplasia is 
limited to comparisons of birth length and adult height to normal population. Reports on body 
proportions in achondroplasia have been scarce and calculating SDS only recently became 
available with references from Argentina81. 
We therefore decided to construct growth and body proportion references from a European 
cohort. Illustrating these also as SDS charts creates insights into timing and magnitude of 
growth restriction caused by the specific FGFR3 mutation. 
4.1.1 Height development in achondroplasia 
Figure 18 illustrates how height in achondroplasia develops from birth to adulthood in the 
present study and in others previously listed in Table 2. Height seems to develop similarly 
with comparable adult height in most studies, but it is difficult to evaluate possible 
differences during infancy or childhood, or in tempo. 
 
Figure 18 Height for age in boys (left) and girls (right) with achondroplasia in cohorts from Europe, North America, 
South America, Asia and Australia. Note that height during the first year of life might appear linear, which is a result 
of values being available only for full chronological ages. 
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Figure 19 Development of height position in achondroplasia relative to normal population in boys (left) and girls 
(right) in cohorts from Europe, North America, South America and Asia 
Height development expressed as SDS, Figure 19, gives thus better information about tempo 
and possible ethnical differences. All studies show identical patterns with comparable tempo. 
Birth length is only marginally affected, which speaks for normal intrauterine growth. 
Postnatal height position decreases abruptly to almost -4 SDS at one year of age and -5 SDS 
at two years of age. Major “loss” in height position occurs during the infancy period and the 
position during childhood ages is generally maintained at about -5 SDS. Adult height is 
remarkable similar among the cohorts (summarised in Table 4), despite differences in data 
collection periods, height of background populations and age for reporting adult height. 
Adolescent height in girls from Argentina and the USA might be an exception. On other 
hand, note that the first achondroplasia studies from the USA69,71 report same female adult 
height as found in this European cohort. Japanese adults with achondroplasia are as tall as 
their peers in other parts of the world. Secular trends or influence of background population is 
thus not or is only marginally detectable in achondroplasia. 
Table 4 Adult height in different achondroplasia cohorts 
Region/ study Age 
Adult height, cm (mean ±SD) 
Sample size 
(male/ female) 
Boys Girls 
Sex 
difference 
Northern Europe 20+ 132.3 ±4.9 124.4 ±4.6 8 cm 91 (36/55) 
USA69 16+ 131.6 ±5.6 123.5 ±6.0 8 cm 108 (52/56) 
USA71 18 130.7 ±6.5 125.2 ±6.0 6 cm n/a 
USA79 15.8 126.7 ±10.1 119.9 ±10.4 7 cm 16 (7/9) 
USA and Canada156 19+ 135.2 ±5.6 125.9 ±3.9 9 cm 27 (16/11) 
UK72 n/a 132.2 ±1.6 123.9 ±1.1 8 cm n/a* 
Japan75 17.8 130.4 ±5.9 124.0 ±5.3 6 cm n/a 
Argentina78 15+ 128.3 ±7.7 119.9 ±7.2 8 cm 54 (21/33) 
Australia80 18 134 ±n/a 125 ±n/a 9 cm 6 (2/4) 
* visually read from figure n=17 (3 male/ 14 female >17.5 years) 
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Yearly increments, Figure 20, as proxy for growth velocity, is thus decreased already during 
the first year of life but progresses subsequently in parallel to the normal height reference. A 
slight pubertal spurt can only be seen in the Japanese reference for girls, which might be 
explained by different fitting techniques. In this Japanese achondroplasia study, individual 
data series were first fitted by eye to obtain height values at full chronological ages from 
which references were then constructed.75 
 
Figure 20 Height in achondroplasia as yearly increments for boys (left) and girls (right) in cohorts from Europe, 
North America, South America and Asia compared to normal population 
Additionally, height position decreases by another SD during pubertal ages (Figure 19), 
which possibly could be explained by extensive height gain in the normal population and a 
smaller absolute pubertal height component in achondroplasia157. Pubertal timing is generally 
normal in achondroplasia, and a growth spurt is also present,71,157 but smaller in absolute 
terms.157 Evaluations of individual height patterns in our material show a clear acceleration 
during normal pubertal ages; i.e. 12 years for boys and 10 year for girls. Total height gain 
from these ages to final height is 18.5/ 17.8 cm respectively in boys and girls (data available 
for 17 boys and 24 girls) or 14.2/ 14.5 percent of adult height. Corresponding pubertal height 
gain calculated from the mean values of our achondroplasia height reference is 18.7 cm for 
both sexes or 14.2/ 15.1 percent of respective adult height. This is comparable to 15.6/ 15.0 
percent in the WHO reference.37 
4.1.2 Leg length and arm span development in achondroplasia 
As noted in section 1.1, secular trends in height are to a great extent related to leg growth.4,5 
In the normal population, only 30 percent of final leg length is attained at one year of age 
(Figure 1), compared to 55 percent of sitting height (as proxy for trunk length). Growth 
velocity for legs is thus normally higher than for trunk during prepubertal ages. Short legs 
and arms with limited growth capacity are, however, a typical feature of achondroplasia. 
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Figure 21 Leg length as yearly increments in (a) normal population references7,152 and (b) achondroplasia cohorts in 
Europe and South America. Note that comparison to existing achondroplasia US studies is not included since these 
traditionally measure upper/lower body segment instead of sitting height and subischial leg length. 
Leg growth, expressed as yearly increments in Figure 21, in achondroplasia is pronouncedly 
lower compared to that of the normal population. Leg length is almost 14 cm shorter at two 
years of age and almost 40 cm at adult ages (Table 5). Half of this final deviation is reached 
between four and six years. Leg length might also be affected by genu varum development, 
which may be caused by knee joint laxity and an uneven growth of tibia and fibula. 
Overgrowth of distal fibula158 might cause varus development of the tibia.159 
Table 5 Deviation of body proportions, in cm, in achondroplasia from normal population at selected ages 
Age 
Leg length Arm span Sitting height 
Boys Girls Boys Girls Boys Girls 
2 years -13.3 -13.6 -13.8 -13.4 -1.5 -1.8 
4 years -18.7 -18.6 -24.7 -24.2 -0.9 -1.6 
6 years -23.3 -23.3 -35.3 -33.6 -1.2 -1.5 
9 years -27.8 -28.5 -41.0 -45.1 -2.0 -2.1 
18 years -39.5 -35.5 -64.5 -63.4 -6.2 -3.9 
Similarly, arm span is about 14 cm shorter than normal at two years of age and almost 65 cm 
at adult ages. In other words, an adult with achondroplasia has roughly 35 percent less range 
of motion compared to a normal adult despite similar sitting height/ trunk length. “Personal 
area” and reach of arms is thus severely restricted, which limits the possibility to managing 
daily tasks, including dressing and taking care of personal hygiene.160,161 An inability of full 
elbow extension might also be contributing to this situation and is frequently reported in 
achondroplasia.58,162 
Note that shoulder breadth constitutes a higher proportion of arm span during younger ages, 
thus contributing to less affected arm span (Figure 22). Absolute size and magnitude of 
growth restriction can therefore not be compared but growth pattern and tempo appear 
otherwise similar in leg length and arm span. Growth is severely compromised already in 
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early ages with leg length at about -7 SDS already at two years and arm span decreasing from 
-3 SDS to -6.5 SDS during prepubertal ages. 
 
Figure 22 Development of leg length and arm span in achondroplasia: expressed (a) as SDS and (b) as yearly 
increments. Note different scaling for both variables as shoulder breadth contributes to arm span. 
4.1.3 Head circumference in achondroplasia 
Head circumference is only marginally increased at birth but accelerates postnatally faster 
compared to the normal population. Over 90 percent of adult head circumference is already 
achieved at two years of age, Figure 23, almost one year earlier than normal. Tempo of head 
growth is thus increased in achondroplasia. 
 
Figure 23 Head circumference in achondroplasia cohorts from Europe, North America and South America: (a) as 
development of mean and (b) as percentage of final size 
The typical macrocephaly is probably a result from FGFR3 influence on CNS growth while 
growth of the skull bone is a secondary adaption. Increased brain tissue volume is also 
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confirmed by MR imaging in school children with achondroplasia.163 Activating mutations in 
FGF receptors give a reduced skull base with premature closure of synchondroses causing a 
narrow foramen magnum.59 Additionally, narrow foramina in the skull base might cause an 
increased venous pressure and a communicating hydrocephalic situation due to increased 
liquor pressure.164 Note that decreased or abolished FGFR3 signalling, as in human CATSHL 
syndrome, results a microcephalic development.165,166 
4.2 CLINICAL CHARTS FOR FOLLOWING HEIGHT AND HEAD 
CIRCUMFERENCE 
The clinical charts are compiled in an achondroplasia growth chart booklet. This booklet 
comprises besides the charts also checklists of medical areas for prospective surveillance, 
adapted from guidelines for health supervision in achondroplasia.167,168 
  
Figure 24 Clinical achondroplasia growth charts for ages 0 to 48 months and 4 to 20 years 
The growth charts layout in Figure 24 combines head circumference, height and weight for 
ages 0 to 48 months as well as height and weight for ages 4 to 20 years. This is achieved by 
using a non-linear age axis for the period 0 to 48 months and a log scale for the y-axes. Gross 
motor development is usually delayed in achondroplasia and should be monitored,169 which 
can be done in a scheme adapted from Todorov et al.169 Similarly, as pubertal timing is 
regarded as normal in achondroplasia,71,157 pubertal development can be recorded in a scheme 
constructed from a recent Northern European reference of normal children.170 
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Figure 25 Height and head circumference development in a growth hormone deficient boy with achondroplasia on 
clinical achondroplasia chart with start of growth hormone treatment at five years of age 
 
 
Figure 26 Height and head circumference development in a girl with combination of achondroplasia and Kabuki 
syndrome on clinical achondroplasia chart 
 
GH Rx
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These charts aim at supporting clinical surveillance of children with achondroplasia since 
possible complicating medical conditions affecting growth should be monitored just as in 
children of normal height. Two examples of aberrant growth pattern are shown in Figure 25 
and Figure 26. The first case is a boy with probable growth hormone deficiency, possibly also 
connected to failure to thrive. Substantial improvements in height position can be observed 
after initiation of growth hormone therapy. The second case is a girl with a head 
circumference clearly developing below normal achondroplasia ranges, indicating that an 
additional syndromic condition might be present. Her pubertal growth is clearly subnormal 
and final height might also be reached earlier. Genetic evaluations in this case confirmed a 
combination of achondroplasia and Kabuki syndrome. 
4.3 DIFFERENT GROWTH PATTERNS WITH COMPARABLE ADULT HEIGHT 
Height development in some skeletal dysplasia with severe short stature might result in 
comparable adult height (Figure 27). Although the growth pattern might differ, the magnitude 
of growth inhibition can cover similar ranges. Height position in pseudoachondroplasia, for 
instance, seems to decrease gradually from birth to adult ages while birth length is severely 
affected in children with defects in SLC26A2 (diastrophic dysplasia) and in collagen type 2 
(spondyloepiphyseal dysplasia congenita), indicating that prenatal growth is affected. 
 
Figure 27 Development of height SDS in references for pseudoachondroplasia (PSACH), diastrophic dysplasia (DTD), 
spondyloepiphyseal dysplasia congenita (SEDC)91 and for boys and girls with achondroplasia 
Considering that the growth pattern of achondroplasia is now rather well studied and known, 
our references could be adopted as a matrix for following children with other extreme short 
stature conditions. Positions for height and other measured variables can then be expressed in 
relation to normal population and achondroplasia references. 
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4.3.1 Pseudoachondroplasia 
The distinct height pattern of PSACH, seen in Figure 27, is also observed in most of the 
children in our cohort (Figure 28). Prenatal and initial postnatal growth is normal, but slows 
down later in infancy. Height position is thereafter gradually lost during the entire growth 
period. It is unusual that a height position is maintained for a longer period, but an abrupt 
decline as typical for achondroplasia is not seen. It is unclear whether adult height is related 
to timing of this slow decrease or if a later onset results in a faster decline. However, it is 
clear that SDS cannot be used to compare individuals of different ages and that adult height 
predictions from current height positions are not meaningful in PSACH. 
 
Figure 28 Height SDS development in (a) 20 boys and (b) 9 girls with pseudoachondroplasia 
Sitting height position progresses within normal ranges in some of the children and becomes 
profoundly short in others (Figure 29). For leg length the group differences become more 
distinct although leg growth is affected in all children. In one group leg length develops 
between -3 and -7 SDS at a constant position, which means that legs continue growing at a 
normal tempo. Legs in the other group grow slower and continuously decrease even beyond   
-7 SD. A milder shortness and body disproportion is typical for multiple epiphyseal dysplasia 
(MED) type 1 that could be regarded as the least affected variant of PSACH. 
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Figure 29 Body proportion development in boys (left) and girls (right) with pseudoachondroplasia: (a-b) sitting height 
SDS and (c-d) leg length SDS 
More than 150 mutations in COMP have been reported but the correlation to auxological 
phenotype is poorly understood and height inhibition varies both between and within 
families. For instance, height in affected family of a four generation consanguineous 
Pakistani family, marked by black contour lines in Figure 30, varies between normal (within 
±2 SD) and extreme short stature (-4 to -6 SDS). Two relatives with homozygous missense 
variants are -10 SDS short.96 
Produced by proliferating and hypertrophic chondrocytes, COMP is a vital coordinating 
constituent of extracellular matrix of the epiphyseal growth plate171 and normally assembles 
in endoplasmatic reticulum (ER) with other matrix proteins for subsequent secretion. A 
mutant COMP may cause retention of this complex resulting in cellular stress promoting 
apoptosis of chondrocytes together with deficient amount and quality of extracellular matrix 
of the growth plate.172–174 
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Figure 30 Height SDS in pseudoachondroplasia (PSACH) and acromesomelic dysplasia type Maroteaux (AMDM) 
cases reported in the literature: (a) 29 boys (blue triangles) and 27 girls (red circles) with PSACH89,90,92–96,175,176 
including sex-combined PSACH reference (purple).91 Scatter symbols with black contour lines indicate membership 
in a large Pakistani family with PSACH all with missense variants in COMP.96 (b) 27 boys (blue triangles) and 19 girls 
(red circles) with AMDM85–88,177–179 with lines indicating longitudinal data series. 
4.3.2 Acromesomelic dysplasia type Maroteaux 
Height development in AMDM resembles that in achondroplasia. A major growth inhibition 
occurs during the first year of life and the height position is maintained during prepubertal 
ages. Body disproportion is not necessarily pronounced since sitting height is more affected 
than in achondroplasia. Head circumference also grows within normal population ranges. 
 
Figure 31 Head circumference and height development of six girls with acromesomelic dysplasia type Maroteaux on 
clinical achondroplasia growth chart 
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Thus, defects in the CNP/NPR-B signalling reflects its importance in growth balancing 
FGFR3 activity. Biallelic loss of NPR2 function results in AMDM, whereas heterozygosity 
may reduce adult height by only 1-1.5 SDS.180,181 About 30 mutations in NPR2 have so far 
been reported for individuals with AMDM with varying auxological phenotypes. Many of 
those results in a reduced number of CNP receptors expressed on the chondrocyte cell surface 
while other variants of NPR-B might have reduced CNP binding capacity.88,182 It is yet 
unknown whether any degree of residual function of the receptor is related to the variability 
in clinical and auxological phenotypes. 
 
Figure 32 Height SDS in acromesomelic dysplasia type Maroteaux: (a) longitudinal series of three boys (triangles) and 
six girls (circles) in this study and (b) 27 boys (blue triangles) and 19 girls (red circles) reported in the literature85–
88,177–179 with lines indicating longitudinal data series. 
It is clear that the phenotype in our cohort, although positive for NPR2 mutation, is not as 
severely affected as reported in the literature, where adult height ranges from -6 to -11 SDS 
(Figure 32). Growth pattern from birth to adulthood is, however, difficult to map from 
occasional measurements in available case reports. Longitudinal data series will be needed to 
investigate growth during pubertal ages as well as ages for attaining adult height. 
4.3.3 Hypochondroplasia 
Hypochondroplasia is thought to be one of the most common skeletal dysplasias although 
reports of individual cases and details on growth are limited in the literature. Diagnosing is 
maybe problematic since radiology might not always be obvious and agreement on diagnostic 
criteria is not consistent.183 Also, a pathogenic variant in FGFR3 is only found in about 70 
percent of all cases, p.Asn540Lys being the most common at about 60 percent.150 No 
mutation in FGFR3 is thus found in a substantial number of cases despite similar radiological 
and clinical phenotypes as typical for p.Asn540Lys.150,184 
Children with p.Asn540Lys often grow at about -3 to -4 SDS and adult height ranges from -1 
to -5 SDS (Figure 33). The negative influence from FGFR3 signalling is emphasized in 
homozygous (p.Asn540Lys) or compound heterozygous (p.Asn540Lys/ p.Gly380Arg) 
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mutations in FGFR3 resulting in severe height retardation (indicated by black contour lines in 
Figure 33). 
 
Figure 33 Height SDS development in hypochondroplasia: (a) 11 boys (triangles) and 4 girls (circles) with FGFR3 
p.Asn450Lys mutation and (b) boys (blue triangles) and girls from the literature83,150,184–190 including homozygous or 
compound heterozygous mutation in FGFR3 (black contour lines)191–196 as well as mean height for 
hypochondroplasia84 and achondroplasia. 
The clinical and radiological phenotype of hypochondroplasia and achondroplasia is 
overlapping,184,197 which can also be seen in Figure 34 showing the growth patterns of four 
boys, three with genetically confirmed hypochondroplasia and one with achondroplasia. Note 
that head circumference is comparable in all four cases. Body disproportion in two boys (with 
p.Lys650Asn in yellow and p.Asn540Lys in red) are, due to longer legs, not as pronounced as 
in the rare p.Tyr278Cys (in blue) and in p.Gly380Arg (in green). 
In this specific example, phenotype of the boy with p.Lys650Asn might be relatively mild but 
other amino acid substitutions in this protein position can result in severe phenotypes. For 
instance, mutations changing lysine (basic amino acid) to glutamic acid (acid amino acid) 
results in thanatophoric dysplasia type II (p.Lys650Glu). A change to methioniene 
(hydrophobic amino acid) may instead result in SADDAN (Severe Achondroplasia with 
Developmental Delay and Acanthosis Nigricans) or thanatophoric dysplasia type I 
(p.Lys650Met). Exchange to glutamine or asparagine (both hydrophilic amino acids) may 
result in milder hypochondroplasia phenotypes (p.Lys650Gln/Asn).185 
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Figure 34 Height and body proportion development in four boys with confirmed FGFR3 mutations; 
hypochondroplasia p.Lys650Asn (in yellow), p.Asn540Lys (in red) and p.Tyr278Cys (in blue) and achondroplasia 
p.Gly380Arg (in green) in clinical achondroplasia charts 
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4.4 WEIGHT AND BMI IN SEVERE SHORT STATURE 
Much of the value of BMI, as measure of relative weight, lies in its development over time 
rather than in absolute position in the BMI chart, which may also be distorted in conditions 
with extreme short stature and/or body disproportion. Short legs will naturally cause 
increased BMI value with achondroplasia as typical example. The meaning of the position in 
the normal BMI curve may then be unclear. 
Table 6 Mean height values and corresponding ages in the normal population 
Height (cm) 90 100 110 120 130 140 
Ca age in normal population 2.5 3.5 5.0 7.0 8.5 10.5 
Thus, the severity of short stature and the severity of disproportion needs to be taken into 
account suggesting that weight for height curves might be more relevant for clinical 
evaluation of relative weight. Yet, it should be kept in mind that also such comparisons are 
not necessarily appropriate since the metabolism changes with age. In other words, the 
metabolic situation of an adult with height of 130 cm would then incorrectly be compared to 
that of a prepubertal child as listed in Table 6. Comparing weight for height in achondroplasia 
to general population reference, for instance, showed that all individuals would be classified 
as “obese” while measures of skinfold thickness suggested only 13 percent.198
 
Figure 35 Clinical achondroplasia BMI chart is based on log scales for BMI axis to give the same space to the upper 
and lower end of the distribution. 
Our achondroplasia specific BMI chart, Figure 35, is constructed on o log scale for the BMI 
axis to balance SD width of both ends of the distribution. As already mentioned, the BMI 
curve is naturally moved upwards and a BMI infancy peak is missing. Note that BMI does 
not necessarily take the distribution of fat tissue into account where abdominal fat might have 
different metabolic impact than fat accumulation in thigh and buttocks, as is typical in 
achondroplasia. In addition, metabolic variables such as blood glucose, triglyceride, free fatty 
acid, cholesterol, insulin and thyroid hormone are normal in achondroplasia despite waist/hip 
ratio indicating abdominal obesity.156,199 Following waist circumference as a measure of 
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abdominal-visceral fat might therefore be valuable but syndrome-specific references are not 
available. Since sitting height usually is only mildly affected, normal population references 
might just be as useful. 
Lastly, skeletal dysplasia specific handicap might also influence the possibility for physical 
activities, which can promote weight gain. The ability to accumulate fat seems to differ 
between various skeletal dysplasias, which might be related to the broad spectrum of 
mutations in genes regulating extracellular matrix proteins, signal transductors or RNA 
processing molecules. The specific pathological gene product might thus influence the 
possibility to accumulate adipose tissue. Individuals with certain matrix protein defects, such 
as for instance in SEDC or osteogenesis imperfecta, seem to have less subcutaneous fat than 
peers with achondroplasia despite similar or worse physical handicap. 
4.5 EXPRESSING CHANGES IN EXTREME BODY DISPROPORTIONS 
Body disproportions are pronounced in children with achondroplasia and often in 
pseudoachondroplasia. Expressing sitting height/ height ratio and its changes can, however, 
be difficult since SD bandwidth in the normal population reference becomes successively 
smaller at the upper end of the distribution. Sitting height/height SDS results thus in extreme 
figures, often above +10 SDS. From a clinical perspective, it might be easier to use multiple 
SD based on central distribution thus neglecting influence of/ adjustment for skewness. 
 
Figure 36 Extremes of SH/H SDS: (a) achondroplasia mean estimated by LMS values and by multiple SD of central 
distribution; (b) extreme SD levels of normal population SH/H reference7 (calculated by LMS values) including 
individual series of a girl with achondroplasia (ACH) and with pseudoachondroplasia (PSACH). 
The problem is illustrated in two examples in Figure 36. Estimating SDS for SH/H mean for 
the achondroplasia reference gives extreme results especially if based on LMS values where 
SH/H develops from +11 to about +20 SDS. Using SD of the central distribution, for instance 
SD bandwidth between +1 and 0 SD or the average of the range between ±2 SD, results in 
high but less extreme values. Note that the progression of the curves is similar with a peak at 
approximate ages at peak height velocity in the normal population. The other example shows 
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SH/H development of a girl with achondroplasia and one with pseudoachondroplasia. SD 
levels of the Dutch normal reference7 were estimated by LMS values to cover same ranges as 
for the two clinical examples. At 20 years of age 2.8 percent units cover the area between +20 
and +15 SDS and 3.4 percent units the area between +15 and +10 SDS (a range of 5 SD!). 
Comparable SD bandwidth between +5 and 0 SDS is 5.8 percent units. 
4.6 CHALLENGES IN CONSTRUCTING SYNDROME-SPECIFIC GROWTH 
CURVES 
Constructing syndrome-specific growth charts also comprises challenges. Achondroplasia 
specific studies, including this one, are generally based on rather small samples. 
Measurements are in many cases collected over decades by one or a few observers, which 
may result in sound data quality that allows a reasonable estimation of mean/ median, yet 
variability and tempo (i.e. also yearly increments) might be difficult to capture from these 
small samples. Data series of an individual can influence both progression and size of the SD 
curve if s/he somewhat deviates from the remaining observations. Measurements during 
pubertal ages are a general problem, which affects the mean curve during adolescent and 
adult ages. Adult height measurements often include data from affected parents and other 
adults, possibly representing another cohort, which influences resulting yearly increments and 
mean values of late adolescent/ adult ages. Yearly increments, as shown in Figure 37, can 
therefore take rather shaky forms and are not necessarily representative. 
 
Figure 37 Sitting height as yearly increments in (a) normal population references7,152 and (b) achondroplasia cohorts 
from Europe and South America 
Also attitudes towards including atypical cases as well as towards smoothing methods 
influence resulting reference values. Exclusion criteria in syndrome-specific growth studies 
might comprise chronic disease, growth promoting therapy, significant neurosurgical 
complications, yet, it is questionable if individuals with atypical growth pattern are (or should 
be) excluded. For instance, should a boy with difficulties to gain weight be included in a 
syndrome-specific reference for which measurements are scarce? Differences in 
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achondroplasia weight references, i.e. no weight gain during puberty or higher weight in 
females despite shorter height than in males (Figure 38), are unlikely to be explained by 
natural/ biological causes. 
 
Figure 38 Weight in achondroplasia cohorts from Europe, North America and South America: (a) development of 
median and (b) as yearly increments of median 
In addition, although estimates of variability might be poor in small samples, our clinical 
achondroplasia charts cover ranges of ±3 SD, which might appear bold. Note however that 
height, head circumference and body proportions were fitted to normal distribution models 
with fixed SD bandwidths. This approach follows an ambition to create a growth matrix for 
following children over time and that is clinically easy to use rather than fitting a perfect 
model from a small sample, which comprises three or four parameters for SDS calculation. 
Lastly, accurate velocity curves are difficult to construct from a small sample with irregular 
measurement periods. Growth velocity per se is a tricky measure since individuals differ in 
growth tempo but also since this variable is sensitive to measuring errors and time interval 
between measuring points. Longitudinal, standardised measurements preferably within three 
months periods are needed to obtain reliable results. 
4.7 AIMS OF SKELETAL DYSPLASIA SPECIFIC GROWTH STUDIES 
Keeping in mind these challenges of constructing syndrome-specific growth charts, it might 
be worthwhile to describe specific phenotypes for research purposes in SDS format. 
Magnitude of growth retardation and syndrome-specific tempo can then be expressed for 
instance in relation to the WHO reference. This reference material is internationally 
acknowledged and has been constructed by state-of-the-art methods. Tabled LMS values are 
available for a detailed age range and no additional interpolation between completed age 
intervals is thus needed. In order words, describing the growth pattern of a certain skeletal 
dysplasia does not necessitate constructing syndrome-specific growth references, which 
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might be based on measurements from different clinical entities from different background 
populations and different measuring techniques. 
From a clinical perspective, the availability of a standardized growth matrix might be more 
important regardless its background population. Future height development is a concern for 
parents when height develops far beyond the normal range. For them and for future planning 
it is important to get a fair forecast of future height development. 
4.8 HEIGHT GAIN THROUGH GROWTH PROMOTING THERAPHY 
Communicating expected treatment outcomes to parents can be problematic if these are 
variable. The second part of this PhD project focuses therefore on evaluating growth 
promoting therapy by characterising good and poor height response to growth hormone 
treatment (GH Rx) in girls with Turner syndrome. 
One of the most important question is how to define and estimate treatment success and 
whether the therapy goal is to normalise final height relative to the normal background 
population (i.e. above -2 SD) or relative to familial target (i.e. MPH ±9 cm for girls) or rather 
to achieve maximal height from treatment.200 Treatment effects can be evaluated based on 
comparisons to control groups or to projected adult height,201 measured in cm or expressed as 
SDS relative to Turner-specific or to normal population references. 
 
Figure 39 Differences in height SDS during pubertal ages if based on conventional or prepubertal (in green) height 
references. Height development in two girls prior treatment (circles without fill), under GH Rx (filled circles) and 
after onset of puberty (black contour lines) is shown. It might also be difficult to differentiate between height gains 
from GH Rx or from pubertal induction.  
Each of these methods comprises drawbacks, as noted in earlier sections. To recall, adult 
height projections from current height position might be imprecise in younger ages also when 
using bone age23,24 and might, if based on historical Turner references, not take into account 
possible effect of secular trends in height. Also since estimates of variability (or SD) are not 
necessarily consistent between syndrome-specific references, resulting SDS can vary greatly 
depending on the choice of reference.202 Likewise calculating SDS from normal population 
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references can be misleading during pubertal ages136 since chronological age, following a 
conveniently linear scale, is a poor proxy for a growth tempo that is regulated by the ovaries 
or testes. Two examples in Figure 39 depict this dilemma. The girl marked in blue starts GH 
Rx at 9.6 years of age and a height position just below the -2 SD line. Height increases by 
almost 1 SD until pubertal onset at 10.4 years and height position after 12 treatment months 
could then be compared to -2 SD (prepubertal line) or -1 SD (conventional line). Similarly, 
the girl marked in red starts GH Rx at 11 years and at a height position of -2.5 (prepubertal 
line) or -3 SDS (conventional line). Height after one year is -1.9 or -2.9 SDS respectively. 
Lastly, it should be noted that the dataset represents a mix of therapy traditions and attitudes 
that might also have been changing over time. Therapy modalities including GH dose, timing 
of pubertal induction or possible concurrent treatment are thus not randomly determined, but 
by the doctor’s perception. This complicates analysis of correlations, interactions or effects 
contributing to total height gain. The focus of this study is thus on describing the variability 
in terms of good and poor responses in respect to variables that generally are claimed to be 
predictive for treatment success. 
 
Figure 40 Age and height (cm) in 413 girls with Turner syndrome at GH Rx start on Swedish growth chart with 
colours indicating three response groups: good (green), poor (red) and intermediate (blue). Note that 5 percent at each 
end of the response distribution were excluded to avoid possible outliers. 
  55 
4.8.1 Age at GH Rx start 
Age at GH Rx start and treatment duration were the most important, but not independent, 
factors of final height (in cm) in a large register-based study.203 Also prediction models, 
developed for clinical guidance, suggest age at treatment initiation as the most important 
factor for total height gain (in cm).204 Measuring height gain from GH Rx start to adult height 
in cm will of course always favour early treatment initiation. 
In this cohort of 455 girls, timing of GH Rx initiation is distributed over almost the whole 
growth period (Figure 40) with about 50 percent starting treatment during (for normal 
population) pubertal ages. It is therefore questionable how valuable a comparison across all 
ages is. In this material more girls with poor response started GH Rx during pubertal ages, 
especially after 14 years of age (28/126 in poor versus 4/129 in good group). It could thus be 
argued that height gain potential is limited after certain ages and that earlier GH Rx start per 
se is not inevitably a predictor for treatment success. Dividing the cohort into those with GH 
Rx start during typically prepubertal (<9.5 years) and pubertal (>9.5 years) ages shows no 
clinically relevant effect of earlier GH Rx initiation on total height gain (Figure 41a and 
Figure 42b). 
 
Figure 41 Pivotal view of good (in green) and poor (in red) response in the younger cohort with GH Rx start <9.5 
years. The aim of this presentation is to compare green versus red not x versus y. 
Note that these pivotal charts are not inconvenient to read as the perception focuses on the 
relationship between x and y instead of on differences between green and red scatters. This 
kind of presentation is, however, interesting for exploring the dispersion of the data in both 
cohorts without necessarily hunting for statistical significance with more or less clinical/ 
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biological relevance. Corresponding descriptive statistics, in form of median and ranges, are 
summarized in Table 7. 
In the younger group, both good and poor responses start GH Rx at comparable ages and 
height positions; 6.7 versus 6.1 years of age and -3.0 versus -2.7 SDS. In the older group, on 
the other hand, good responses is clustered at earlier ages and lower height positions; 11.3 
versus 12.9 years of age and -3.1 versus -2.3 SDS. Following a cluster of poor response with 
late GH Rx start (marked in orange box) suggests that final height is comparable to good 
response. No clinical relevant difference is neither seen for initial treatment response, MPH 
or age at pubertal onset between good and poor response in this older group. 
Table 7 Median and range for variables previously suggested to be predictive for GH Rx success and partly shown as 
scatters in Figure 41 and Figure 42 
 GH Rx start <9.5 years  GH Rx start >9.5 years 
 good response poor response  good response poor response 
 n median range n median range  n median range n median range 
  MPH 41 -0.2 -2.9 1.1 57 -0.6 -3.3 1.2  53 -0.1 -2.6 1.6 48 -0.3 -2.9 1.2 
GH Rx start 
  Age 43 6.7 3.7 9.5 58 6.1 3.6 9.4  56 11.3 9.5 15.2 51 12.9 9.8 16.5 
  Height SDS 43 -3.0 -5.4 -1.5 58 -2.7 -4.9 -1.0  56 -3.1 -4.2 -1.4 51 -2.3 -4.6 -0.7 
  MPH SDS 41 -2.8 -3.7 -1.8 57 -2.3 -3.8 0.2  53 -2.8 -3.3 0.4 48 -2.0 -3.3 0.9 
Dose (µg/kg/day) 
  at 12 months 41 53.2 32.2 74.1 54 39.9 24.7 71.9  53 46.4 25.0 72.9 44 34.0 14.9 67.6 
Age at Pubertal onset 
  all 43 13.9 10.4 16.0 55 13.4 8.9 16.8  54 14.9 10.5 21.6 50 14.6 10.5 18.1 
  spontaneous 3 12.8 10.7 14.1 10 11.0 8.9 14.9  13 13.2 10.5 21.6 18 13.0 11.4 18.1 
  induced 40 13.9 10.4 16.0 45 13.9 10.8 16.8  41 15.0 11.3 18.1 32 15.3 10.5 17.8 
Adult height 
  Age 43 16.3 15.0 18.9 58 16.3 14.3 18.6  56 17.1 15.4 21.7 51 17.0 15.0 21.3 
  Height SDS 43 -1.2 -3.3 0.4 58 -2.2 -4.7 -0.9  56 -1.3 -2.8 0.3 51 -2.3 -4.5 -0.7 
  Height cm 43 159.3 145.5 169.0 58 152.7 136.2 161.8  56 158.8 150.5 169.2 51 152.9 138.4 163.5 
  MPH SDS 41 -0.8 -2.0 0.3 57 -1.7 -3.5 0.9  53 -1.1 -3.3 0.4 48 -1.9 -3.4 0.5 
Body proportions 
 At GH Rx start 
  SH SDS 37 -1.7 -3.3 0.2 44 -1.4 -3.1 0.4  42 -2.2 -3.4 1.0 37 -1.9 -4.9 -0.4 
  SILL SDS 37 -3.5 -5.9 -1.8 44 -3.4 -5.0 -2.0  42 -4.0 -6.8 -2.0 37 -3.5 -4.5 -1.7 
  SH/H SDS 37 2.5 0.0 4.3 44 2.5 -0.5 5.0  42 2.6 0.3 14.8 37 2.3 -0.9 6.2 
 At adult height 
  SH SDS 32 -0.2 -2.2 1.3 44 -0.8 -3.5 0.8  36 -0.6 -1.9 1.0 34 -1.2 -4.0 0.6 
  SILL SDS 32 -2.0 -3.2 -0.6 44 -2.7 -4.6 -1.2  36 -2.0 -3.1 -0.3 34 -2.5 -4.8 -1.0 
  SH/H SDS 32 2.0 -0.4 4.6 44 2.6 -0.8 6.6  36 2.0 -0.7 3.6 34 1.9 -0.5 4.5 
Delta Height SDS 
  total Rx 43 1.9 1.6 2.3 58 0.5 0.0 0.9  56 1.7 1.4 2.3 51 0.2 -0.5 0.4 
  first year 41 0.8 -0.1 1.2 54 0.6 0.0 1.7  54 0.9 0.3 1.2 47 0.7 0.0 1.1 
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Figure 42 Pivotal view of good (in green) and poor (in red) response in the older cohort with GH Rx start >9.5 years. 
The aim of this presentation is to compare green versus red not x versus y. 
4.8.2 Height at GH Rx start and MPH 
MPH and a normal child’s actual height position are important predictors of his/her adult 
height, as noted in section 1.2, and the same is observed in non GH-treated girls with Turner 
syndrome. Correlation between parents and girls is comparable to that of the normal 
population despite constant height loss.119,205 Regression slopes between earlier height 
position and adult height varies between 1.13 (R-squared 0.9)25 and 0.84 (R-squared 0.64)24 
in non GH-treated girls with Turner syndrome. Note that height at GH Rx start is the main 
determinant in existing prediction model for final height (in cm) but only fifth rank of total 
height gain.204 Similarly, taller final height is related to taller parents in some studies,204,206 
but not in others.145 
In this study, MPH SDS is related to adult height SDS (Figure 41c and Figure 42g) and is in 
good and poor response respectively -0.2 versus -0.6 SDS in the younger group and -0.1 
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versus -0.3 SDS in the older group. The natural relationship between earlier height and adult 
height positions are maintained ((Figure 41b and Figure 42c); regression slopes are well 
above 0.9 and R-squared around 0.9. Considering that short stature is not a pathologic 
condition per se, it is tempting to speculate that this natural relationship is not disturbed in 
Turner syndrome. In an age-matched group with tumor cerebri, in contrast, the slope is 0.8 
with R-squared only 0.3 suggesting a “disturbance” by disease and/or its treatment 
(unpublished data from the Swedish National Register for growth hormone treatment of 
children and adolescents). 
Interesting to note is that the curves for good and poor response progress perfectly in parallel 
to each other, both in the younger and older cohort. The space between the response groups 
composes the intermediate group; i.e. 40 percent of the central distribution (marked in blue in 
Figure 17 but not added to Figure 41b and Figure 42c). In other words, the natural 
relationship between height SDS at GH Rx start and adult height is maintained while upper 
and lower side of this relationship constitute good and poor treatment response. 
 
Figure 43 Height position in those with good (green) and poor (red) response at birth and first years of age, GH Rx 
start, after 12 months GH Rx and at adult height compared to target: in (a) the young cohort with GH Rx start < 9.5 
years of age and (b) in the older cohort with GH Rx start >9.5 years of age. Note that height progression beyond 
selected time periods is not investigated nor expected to be linear and is therefore marked by dashed lines. 
4.8.3 Increased tempo versus height position 
First year’s treatment response in height is generally regarded as determinant for long-term 
response207,208 and is therefore valuable for guiding further actions; i.e. for doctors to 
recommend continuation of treatment, for policy maker to agree to financial support and for 
families to stay motivated to continuing necessary activities related to GH therapy. 
Delta height SDS from first treatment year, Figure 43, is comparable in both response groups 
of the younger cohort, 0.8 versus 0.6 SDS. Those with good response continue improving 
their height position and resulting final height is approximately 1 SDS below MPH, which 
might be within familial target range. A similar initial gain, 0.9 SDS, is seen for good 
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responses in the older group. Yet, height gain in both poor groups seems to be only 
temporary. Important to note that in this older cohort height SDS after 12 treatment months 
could be distorted by effects of pubertal induction making it difficult to differentiate whether 
the increase in height SDS is due to effect of GH Rx or due to induced pubertal spurt. 
4.8.4 Remaining questions 
The current study refrains from reporting effects of oxandrolone therapy since this factor was 
not reported as determinant of height outcome in prediction models from KIGS.204 Yet, 
evidence from several RCT’s suggests increase in final height by oxandrolone,42,209 possibly 
associated to improvements in sitting height rather than leg length.210 The proportion of such 
treatment was noteworthy in our cohort, 29/43 versus 34/58 in the younger group and 40/56 
versus 20/51 in the older group, and should thus investigated further. 
Sitting height/height ratio in untreated girls with Turner syndrome normalises from 56.9 
percent at ten years of age (+3.9 SDS) to 53.7 percent at adulthood (+0.8 SDS).132 In this 
study, sitting height/height ratio improved for good response in both age groups, from 2.5/2.6 
SDS for younger/ older at GH Rx start to 2.0/2.0 SDS at adult height. This development 
indicates a preference for trunk growth in the good response group whether depending on GH 
Rx, estrogens or oxandrolone or being inherent by the skeletal dysplasia background in 
Turner syndrome has to be studied further. 
A randomized dose-response trial using three GH dose regimes, 45/45/45, 45/68/68 and 
45/68/90 µg/kg/day for first/ second year/ thereafter, showed higher height gain in both 
higher dose groups leaving IGF-I levels above normal ranges.145 GH dose is this study is not 
controlled by a standardised protocol. Total GH dose may be difficult to estimate from 
register data and it is furthermore probable that GH dose per kg is not maintained for those 
with good response and that higher GH dose is given to those considered to have insufficient 
response. This makes it of course not meaningful to group the total cohort in GH dose 
cohorts. Also in KIGS prediction models, GH dose has little weight for final height or height 
gain from treatment.204 
Similarly, data on IGF-I and karyotype was insufficient for analysis in this study. Differences 
in treatment response associated to karyotype were suggested by one study211 but not by 
others.145,203,204,212,213 Investigating changes in IGF-I levels is essential considering that GH 
secretion in girls with Turner syndrome is generally normal201 and that low IGF-I levels 
instead might be connected to a slower spontaneous tempo in growth. 
 
  61 
5 CONCLUDING REMARKS 
Growth charts are essential for following children in clinical work and for evaluating growth 
promoting therapy. Syndrome-specific growth charts are helpful in situations where growth 
develops far below the normal population range, such as in skeletal dysplasias with extreme 
short stature. 
Growth and body proportion references from the present European achondroplasia cohort, the 
first with a detailed description of periods with growth restriction relative to normal growth 
from birth to adulthood, suggest that  
 tempo in head size is increased attaining final size earlier than normal 
 height position is especially compromised during first years of life 
 leg length at adult ages is roughly 50 percent shorter than normal 
 arm span at adult ages is almost 35 percent shorter than normal, despite almost 
normal trunk height, thus severely restricting personal area of access 
 pronounced body disproportions distort the BMI value, with a median developing 
above internationally accepted cut-off levels for overweight 
Clinical charts are partly constructed on non-linear age scales and logarithmic scales for y-
axes with the intention to 
 capture growth pattern during infancy when growth velocity is highest 
 enable simultaneous evaluation of length, weight and head circumference 
development 
 give same resolution/space for positional BMI changes within lower versus higher 
distribution 
 facilitate plotting and reading sensitivity. 
Presented growth chart compilation will support clinical surveillance of children with 
achondroplasia and other severe short stature conditions for which syndrome-specific charts 
are missing. Using achondroplasia growth charts as a short stature matrix suggests 
 height inhibition in acromesomelic dysplasia type Maroteaux is also compromised 
during first years of life and height in some cases resembles that in achondroplasia 
 height position in pseudoachondroplasia decreases, after an initial period of normal 
growth, gradually until adult height, which makes adult height predictions from 
previous height position impossible 
 auxological phenotype in hypochondroplasia is pronounced heterogeneous ranging 
from almost normal stature to phenotypes similar to achondroplasia. 
Syndrome-specific charts are often based on small samples making estimates of variability 
not necessarily robust. This can affect calculation of changes in growth positions based on 
SDS. Evaluation of growth hormone treatment in girls with Turner syndrome might therefore 
better be based on normal population references using prepubertal SD lines for calculating 
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height position at treatment start during normally pubertal ages. Analysing total height gain 
from treatment to distinguish between good and poor response shows that 
 growth hormone treatment is initiated over the wide range of ages covering childhood 
and pubertal ages 
 early start of GH might not result in better total height gain 
 initial height gain might be temporary in a noteworthy proportion of girls with Turner 
syndrome and is not translated to total height gain 
 register data reflects treatment attitudes and traditions making it difficult to assign 
effects to treatment modalities such as GH dose 
For the future, regular measurements of auxological variables including sitting height and 
arm span are encouraged in order to increase knowledge in growth and body proportion 
patterns in different skeletal dysplasia entities. Likewise, the background for variability in 
response to GH treatment in non-GH deficient children needs further investigation. 
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